Composition and method for treatment of inflammatory and autoimmune disorders

Abstract

The present invention relates generally to the field of therapeutic compositions comprising bacterial strains and methods for the treatment or prevention of disease More particularly, the present invention relates to compositions comprising purified bacterial strains isolated from the mouse gut and their use in the treatment or prevention of inflammatory and autoimmune disorders. In one aspect of the invention the composition comprising bacterial mixture of genus Bacillus and genus Streptococcus. In one aspect of the invention provides combination of bacterial species from genus Bacillus and genus Streptococcus.

Description

[0001] Composition and method for treatment of inflammatory and autoimmune disorders FIELD OF THE INVENTION This invention relates generally to the field of therapeutic compositions comprising bacterial strains and methods for the treatment or prevention of disease. More particularly, the present invention relates to compositions comprising purified bacterial strains isolated from the mouse gut and their use in the treatment or prevention of inflammatory and autoimmune disorders. In one aspect of the invention the composition comprising bacterial mixture of genus Bacillus and genus Streptococcus. In one aspect of the invention provides combination of bacterial species from genus Bacillus and genus Streptococcus. BACKGROUND OF THE INVENTION The human intestinal microbiome comprises tens of trillions of bacteria from over 1000 identified species. The composition of an individual’s microbiome is as unique as a fingerprint, with wide variety existing between even close relatives. The human intestine is thought to be sterile in utero, but it is exposed to a large variety of maternal and environmental microbes immediately after birth. Thereafter, a dynamic period of microbial colonization and succession occurs, which is influenced by factors such as delivery mode, environment, diet and host genotype, all of which impact upon the composition of the gut microbiota, particularly during early life. Subsequently, the microbiota stabilizes and becomes adult-like [1]. The human gut microbiota contains more than 500-1000 different phylotypes belonging essentially to two major bacterial divisions, the Bacteroidetes and the Firmicutes [2]. The successful symbiotic relationships arising from bacterial colonization of the human gut have yielded a wide variety of metabolic, structural, protective and other beneficial functions. The enhanced metabolic activities of the colonized gut ensure that otherwise indigestible dietary components are degraded with release of by-products providing an important nutrient source for the host. Similarly, the immunological importance of the gut microbiota is well-recognized and is exemplified in germfree animals which have an impaired immune system that is functionally reconstituted following the introduction of commensal bacteria [3-5]. Dramatic changes in microbiota composition have been documented in gastrointestinal disorders such as inflammatory bowel disease (IBD). For example, the levels of Clostridium cluster XrVa bacteria are reduced in IBD patients whilst numbers of Escherichia coli are increased, suggesting a shift in the balance of symbionts and pathobionts within the gut [6-9]. Interestingly, this microbial dysbiosis is also associated with imbalances in T effector cell populations. In recognition of the potential positive effect that certain bacterial strains may have on the animal gut, various strains have been proposed for use in the treatment of various diseases [10-13]. Also, certain strains, including mostly Lactobacillus and Bifidobacterium strains, have been proposed for use in treating various inflammatory and autoimmune diseases that are not directly linked to the intestines

[0014] ,

[0015] . However, the relationship between different diseases and different bacterial strains, and the precise effects of particular bacterial strains on the gut and at a systemic level and on any particular types of diseases, are poorly characterized. Cook et. al.

[0016] speculates that bacteria obtained from faecal samples may be useful for treating immune system disorders but no guidance are provided as to which bacteria would be effective. Honda et al.

[0017] describes how a mixture of 20 bacteria of different genera, including species from the Clostridium genus, induce the proliferation and accumulation of Th17 cells. Honda et al.'s compositions are said to be useful for improving immune functions and preventing or treating infectious diseases. However, Honda et al. shows that in order to treat autoimmune and inflammatory disease in an individual, the Th17-inducing bacteria should be inhibited or killed, for example, by administering an antibiotic to the patient. IBD (including the two major disease subtypes Crohn's disease (CD) and ulcerative colitis (UC)) is characterized by episodic and disabling inflammation of the GI tract. In 2017, it is estimated that 6.8 million people globally suffered from IBD, with the highest prevalence in the United States and Europe

[0018] . In 2025, it is reported that IBD is a growing global health challenge affecting more than 7 million people worldwide

[0021] . Up to 20% of patients are diagnosed before the age of 16 and pediatric-onset IBD (PIBD) is associated with a more complicated and aggressive disease with adverse impacts on growth and psychosocial development. There is currently no cure for IBD, and long-term clinical management requires effective therapeutics with an excellent safety profile. However, existing treatments show a range of deficiencies and remission is generally short. Moreover, IBD therapeutics are ineffective where early onset coupled with more aggressive disease result in progressive bowel damage and need for surgery. There is an urgent need to develop more effective and safe therapies to improve patient quality of life, maintain remission over long periods, reduce surgery and curtail individual and public health costs. Existing treatments for IBD are sub-optimal with strong adverse effects, low compliance (50% average non-adherence rates

[0019] and high cost. Furthermore, there is no effective solution to maintaining extended periods of disease-free remission. Mesalamine, one of the most widely used first line therapies for mild to moderate flares of ulcerative colitis and for maintenance of remission, has response rates between 40%-70% and remission rates of 15%-20%

[0020] . There is a requirement in the art for new methods of treating inflammatory and autoimmune disorders. There is also a requirement for the potential effects of gut bacteria to be characterized so that new therapies using gut bacteria can be developed. Definitions: The term “pharmaceutical composition” refers to preparations which are in such form as to permit the biological activity of the active ingredients, for example isolated bacteria or bacterial mixture are the active ingredients in the present invention, to be unequivocally effective, and which contain no additional components which are significantly toxic to the subjects to which the formulation would be administered. The term “pharmaceutical composition”, or “composition” or “pharmaceutical formulation” or “formulation”, can be used here interchangeably. The composition as disclosed here in the present invention may or may not comprise additional excipients other than bacterial mixture or bacterial combination(s) as disclosed elsewhere herein this description. The terms “patient” and “subject” are used interchangeably and are used in their conventional sense to refer to a living organism suffering from or prone to a condition that can be prevented or treated by administration of a composition of the present invention and includes animals. The terms “excipients” or “pharmaceutical excipients” can be used interchangeably and are inert agents other than active ingredients that includes but not limited to vehicles, fillers, binders, disintegrants, pH adjusting substances, buffers, solvents, solubilizing agents, sweeteners, coloring agents, and any other inactive agents that can be included in pharmaceutical dosage forms. The term “ZMT” is an in-house code given to bacterial strain as mentioned here in below; ZMT culture ID MTCC number Culture identity ZMT148 MTCC 25860 Bacillus velezensis ZMT141 MTCC 25861 Enterobacter hormaechei ZMT114 MTCC 25870 Streptococcus infantarius ZMT122 MTCC 25872 Bacillus subtilis ZMT128 MTCC 25873 Bacillus subtilis ZMT129 MTCC 25874 Bacillus subtilis ZMT121 MTCC 25871 Streptococcus thermophilus ZMT116 Not available Bacillus subtilis e.g. ZMT148 is an in-house code created which corresponds to bacterial strain Bacillus velezensis. The MTCC assigned number for the said strain is MTCC 25860. Therefore, it is depicted as ZMT148 which corresponds to MTCC 25860. The combination of bacterial strains e.g. ZMT129 + ZMT121 denotes bacterial mixture of Bacillus subtilis and Streptococcus thermophilus wherein Bacillus subtilis having MTCC assigned number MTCC 25874 which corresponds to ZMT129 and Streptococcus thermophilus having MTCC assigned number MTCC 25871 which corresponds to ZMT121. The other bacterial strains of the present invention can be also identified in same manner. Figures of the present invention Figure 1: The effect of cytokine induced barrier damage protection using individual bacterial strain ZMT121, ZMT122, and ZMT129 at 107CFU normalized against sodium butyrate (8 mM) as a positive control. Figure 2: The effect of cytokine induced barrier damage protection using various doses of combined bacterial species of ZMT121 and ZMT122 (ZMT121 + ZMT122) and combined bacterial species of ZMT121 and ZMT129 (ZMT121+ZMT129) normalized against sodium butyrate (8 mM) as a positive control. Figure 3: Study of E.coli induced barrier damage using 108CFU combined bacterial species of ZMT129 and ZMT121 (ZMT129 + ZMT121), 108CFU Visbiome normalized against sodium butyrate (8 mM) as a positive control. Figure 4: Study of E.coli induced barrier damage in presence of immune cells using 108CFU combined bacterial species of ZMT129 and ZMT121 (ZMT129 + ZMT121), 108CFU Visbiome normalized against sodium butyrate (8 mM) as a positive control. OBJECTIVE OF THE INVENTION In an embodiment the present invention provides a pharmaceutical composition comprising purified bacterial mixture of the genus Bacillus and genus Streptococcus. In an embodiment the present invention provides a pharmaceutical composition comprising purified bacterial mixture of the genus Bacillus and genus Streptococcus and optionally one or more bacterial strain from suitable genus wherein said genus can be aerobic and / or anaerobic. In an embodiment the present invention provides a pharmaceutical composition comprising purified bacterial mixture of the genus Bacillus and genus Streptococcus and optionally one or more bacterial strains from the genus selected from Lactobacillus, Leuconostoc, Lactococcus, Enterococcus, Weissella, Pediococcus, Aerococcus, Sporolactobacillus and Bifidobacterium family or any combination thereof. In an embodiment the present invention provides a pharmaceutical composition comprising purified bacterial mixture of the genus Bacillus and genus Streptococcus family and optionally one or more bacterial species selected from Lactobacillus acidophilus, Lactobacillus crispatus, Lactobacillus delbrueckii, Lactobacillus gasseri, Lactobacillus helveticus, Lactobacillus jensenii, Lactobacillus johnsonii, Lactobacillus rogosae, Lactobacillus thermophilus, Lacticaseibacillus casei, Ligilactobacillus salivarius, Limosilactobacillus fermentum, Lacticaseibacillus rhamnosus (previously Lactobacillus rhamnosus), Limosilactobacillus reuteri, Weissella viridescens, Bifidobacterium animalis, Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium choerinum, Bifidobacterium cuniculi, Bifidobacterium dentium, Bifidobacterium faecale, Bifidobacterium indicum, Bifidobacterium longum, Bifidobacterium magnum, Bifidobacterium pseudocatenulatum, Bifidobacterium pseudolongum, Bifidobacterium pullorum. In an embodiment the present invention provides a pharmaceutical composition comprising purified bacterial mixture of the genus Bacillus, species of genus Streptococcus selected from Streptococcus acidominimus, Streptococcus agalactiae, Streptococcus anginosus, Streptococcus avium, Streptococcus bovis, Streptococcus canis, Streptococcus caprae, Streptococcus caprinus, Streptococcus castoreus, Streptococcus caviae, Streptococcus cecorum, Streptococcus cremoris, Streptococcus criceti, Streptococcus dentisani, Streptococcus difficile, Streptococcus durans, Streptococcus dysgalactiae, Streptococcus entericus, Streptococcus epidermidis, Streptococcus equi, Streptococcus faecalis, Streptococcus faecium, Streptococcus ferus, Streptococcus gallinarum, Streptococcus gallolyticus, Streptococcus halotolerans, Streptococcus hansenii, Streptococcus hillyeri, Streptococcus himalayensis, Streptococcus hominis, Streptococcus humanilactis, Streptococcus hyointestinalis, Streptococcus hyovaginalis, Streptococcus ilei, Streptococcus infantis, Streptococcus intermedius, Streptococcus intestinalis, Streptococcus lactis, Streptococcus merionis, Streptococcus microaerophilica, Streptococcus mitis, Streptococcus morbillorum, Streptococcus moroccensis, Streptococcus mutans, Streptococcus oligofermentans, Streptococcus oralis, Streptococcus ovis, Streptococcus pacificus, Streptococcus panodentis, Streptococcus parasanguinis, Streptococcus parasanguis, Streptococcus parasuis, Streptococcus parauberis, Streptococcus parvulus, Streptococcus pasteurianus, Streptococcus peroris, Streptococcus plantarum, Streptococcus pyogenes, Streptococcus respiraculi, Streptococcus saccharolyticus, Streptococcus salivarius, Streptococcus saliviloxodontae, Streptococcus sanguinis, Streptococcus sciuri, Streptococcus sinensis, Streptococcus sobrinus, Streptococcus suis, Streptococcus thalassemiae, Streptococcus thermophilus, Streptococcus thoraltensis, Streptococcus uberis, Streptococcus urinalis, Streptococcus ursoris, Streptococcus vaginalis, Streptococcus varani, Streptococcus vestibularis, Streptococcus vicugnae, Streptococcus vulneris, Streptococcus waius, Streptococcus xiaochunlingii, Streptococcus zalophi, Peptostreptococcus anaerobius, Peptostreptococcus asaccharolyticus, Peptostreptococcus faecalis, Peptostreptococcus harei, Peptostreptococcus heliotrinreducens, Peptostreptococcus magnus, Peptostreptococcus octavius, Peptostreptococcus parvulus, Peptostreptococcus porci, Peptostreptococcus prevotii, Peptostreptococcus russellii, Peptostreptococcus stomatis, Peptostreptococcus tetradius, Peptostreptococcus vaginalis, Streptococcus anginosus subsp. anginosus, Streptococcus constellatus subsp. pharyngis, Streptococcus dysgalactiae subsp. dysgalactiae, Streptococcus equi subsp. equi, Streptococcus faecium subsp. casseliflavus, Streptococcus gallolyticus subsp. gallolyticus, Streptococcus halichoeri subsp. halichoeri, Streptococcus infantarius subsp. coli, Streptococcus infantarius subsp. infantarius, Streptococcus lactis subsp. cremoris, Streptococcus lactis subsp. lactis, Streptococcus mutans subsp. sobrinus, Streptococcus oralis subsp. oralis, Streptococcus phocae subsp. salmonis, Streptococcus salivarius subsp. salivarius or Streptococcus salivarius subsp. thermophilus and optionally one or more bacterial genus selected from Lactobacillus, Leuconostoc, Lactococcus, Enterococcus, Weissella, Pediococcus, Aerococcus, Sporolactobacillus and Bifidobacterium. In an embodiment the present invention provides a pharmaceutical composition comprising purified bacterial mixture of the genus Streptococcus and the species of genus Bacillus selected from Bacillus acidocaldarius, Bacillus amyloliquefaciens, Bacillus amylolyticus, Bacillus anthracis, Bacillus aryabhattai , Bacillus cereus, Bacillus fusiformis, Bacillus globisporus, Bacillus hominis , Bacillus infantis, Bacillus insolitus, Bacillus larvae, Bacillus laterosporus, Bacillus lentimorbus, Bacillus lentus, Bacillus licheniformis, Bacillus macerans, Bacillus macquariensis, Bacillus megaterium, Bacillus mesophilus, Bacillus methylotrophicus, Bacillus multiformis, Bacillus mycoides, Bacillus oceani, Bacillus pantothenticus, Bacillus paralicheniformis, Bacillus paramycoides, Bacillus pasteurii, Bacillus perfringens, Bacillus polyfermenticus, Bacillus polymyxa, Bacillus popilliae, Bacillus pumilus, Bacillus pyogenes, Bacillus sanguinis, Bacillus siamensis, Bacillus spizizenii, Bacillus sporogenes, Bacillus stearothermophilus, Bacillus subtilis, Bacillus tequilensis, Bacillus thermoaerophilus, Bacillus thermodenitrificans, Bacillus thermolactis, Bacillus thermophilus, Bacillus thermotolerans, Bacillus thetaiotaomicron, Bacillus thuringiensis and optionally one or more bacterial genus selected from Lactobacillus, Leuconostoc, Lactococcus, Enterococcus, Weissella, Pediococcus, Aerococcus, Sporolactobacillus and Bifidobacterium. In an embodiment the present invention provides a pharmaceutical composition comprising purified bacterial mixture of the species of genus Bacillus selected from Bacillus acidocaldarius, Bacillus amyloliquefaciens, Bacillus amylolyticus, Bacillus anthracis, Bacillus aryabhattai, Bacillus cereus, Bacillus fusiformis, Bacillus globisporus, Bacillus hominis, Bacillus infantis, Bacillus insolitus, Bacillus larvae, Bacillus laterosporus, Bacillus lentimorbus, Bacillus lentus, Bacillus licheniformis, Bacillus macerans, Bacillus macquariensis, Bacillus megaterium, Bacillus mesophilus, Bacillus methylotrophicus, Bacillus multiformis, Bacillus mycoides, Bacillus oceani, Bacillus pantothenticus, Bacillus paralicheniformis, Bacillus paramycoides, Bacillus pasteurii, Bacillus perfringens, Bacillus polyfermenticus, Bacillus polymyxa, Bacillus popilliae, Bacillus pumilus, Bacillus pyogenes, Bacillus sanguinis, Bacillus siamensis, Bacillus velezensis, Bacillus spizizenii, Bacillus sporogenes, Bacillus stearothermophilus, Bacillus subtilis, Bacillus tequilensis, Bacillus thermoaerophilus, Bacillus thermodenitrificans, Bacillus thermolactis, Bacillus thermophilus, Bacillus thermotolerans, Bacillus thetaiotaomicron or Bacillus thuringiensis, Bacillus velezensis species of genus Streptococcus selected from Streptococcus acidominimus, Streptococcus agalactiae, Streptococcus anginosus, Streptococcus avium, Streptococcus bovis, Streptococcus canis, Streptococcus caprae, Streptococcus caprinus, Streptococcus castoreus, Streptococcus caviae, Streptococcus cecorum, Streptococcus cremoris, Streptococcus criceti, Streptococcus dentisani, Streptococcus difficile, Streptococcus durans, Streptococcus dysgalactiae, Streptococcus entericus, Streptococcus epidermidis, Streptococcus equi, Streptococcus faecalis, Streptococcus faecium, Streptococcus ferus, Streptococcus gallinarum, Streptococcus gallolyticus, Streptococcus halotolerans, Streptococcus hansenii, Streptococcus hillyeri, Streptococcus himalayensis, Streptococcus hominis, Streptococcus humanilactis, Streptococcus hyointestinalis, Streptococcus hyovaginalis, Streptococcus ilei, Streptococcus infantis, Streptococcus intermedius, Streptococcus intestinalis, Streptococcus lactis, Streptococcus merionis, Streptococcus microaerophilica, Streptococcus mitis, Streptococcus morbillorum, Streptococcus moroccensis, Streptococcus mutans, Streptococcus oligofermentans, Streptococcus oralis, Streptococcus ovis, Streptococcus pacificus, Streptococcus panodentis, Streptococcus parasanguinis, Streptococcus parasanguis, Streptococcus parasuis, Streptococcus parauberis, Streptococcus parvulus, Streptococcus pasteurianus, Streptococcus peroris, Streptococcus plantarum, Streptococcus pyogenes, Streptococcus respiraculi, Streptococcus saccharolyticus, Streptococcus salivarius, Streptococcus saliviloxodontae, Streptococcus sanguinis, Streptococcus sciuri, Streptococcus sinensis, Streptococcus sobrinus, Streptococcus suis, Streptococcus thalassemiae, Streptococcus thermophilus, Streptococcus thoraltensis, Streptococcus uberis, Streptococcus urinalis, Streptococcus ursoris, Streptococcus vaginalis, Streptococcus varani, Streptococcus vestibularis, Streptococcus vicugnae, Streptococcus vulneris, Streptococcus waius, Streptococcus xiaochunlingii, Streptococcus zalophi, Peptostreptococcus anaerobius, Peptostreptococcus asaccharolyticus, Peptostreptococcus faecalis, Peptostreptococcus harei, Peptostreptococcus heliotrinreducens, Peptostreptococcus magnus, Peptostreptococcus octavius, Peptostreptococcus parvulus, Peptostreptococcus porci, Peptostreptococcus prevotii, Peptostreptococcus russellii, Peptostreptococcus stomatis, Peptostreptococcus tetradius, Peptostreptococcus vaginalis, Streptococcus anginosus subsp. anginosus, Streptococcus constellatus subsp. pharyngis, Streptococcus dysgalactiae subsp. dysgalactiae, Streptococcus equi subsp. equi, Streptococcus faecium subsp. casseliflavus, Streptococcus gallolyticus subsp. gallolyticus, Streptococcus halichoeri subsp. halichoeri, Streptococcus infantarius subsp. coli, Streptococcus infantarius subsp. infantarius, Streptococcus lactis subsp. cremoris, Streptococcus lactis subsp. lactis, Streptococcus mutans subsp. sobrinus, Streptococcus oralis subsp. oralis, Streptococcus phocae subsp. salmonis, Streptococcus salivarius subsp. Salivarius or Streptococcus salivarius subsp. Thermophilus and optionally one or more bacterial genus selected from Lactobacillus, Leuconostoc, Lactococcus, Enterococcus, Weissella, Pediococcus, Aerococcus, Sporolactobacillus and Bifidobacterium families. In an embodiment the present invention provides a pharmaceutical composition comprising purified bacterial mixture of the species of genus Streptococcus and species of genus Bacillus wherein species of genus Bacillus is selected from Bacillus acidocaldarius, Bacillus amyloliquefaciens, Bacillus amylolyticus, Bacillus anthracis, Bacillus aryabhattai, Bacillus cereus, Bacillus fusiformis, Bacillus globisporus, Bacillus hominis, Bacillus infantis, Bacillus insolitus, Bacillus larvae, Bacillus laterosporus, Bacillus lentimorbus, Bacillus lentus, Bacillus licheniformis, Bacillus macerans, Bacillus macquariensis, Bacillus megaterium, Bacillus mesophilus, Bacillus methylotrophicus, Bacillus multiformis, Bacillus mycoides, Bacillus oceani, Bacillus pantothenticus, Bacillus paralicheniformis, Bacillus paramycoides, Bacillus pasteurii, Bacillus perfringens, Bacillus polyfermenticus, Bacillus polymyxa, Bacillus popilliae, Bacillus pumilus, Bacillus pyogenes, Bacillus sanguinis, Bacillus siamensis, Bacillus spizizenii, Bacillus sporogenes, Bacillus stearothermophilus, Bacillus subtilis, Bacillus tequilensis, Bacillus thermoaerophilus, Bacillus thermodenitrificans, Bacillus thermolactis, Bacillus thermophilus, Bacillus thermotolerans, Bacillus thetaiotaomicron or Bacillus thuringiensis, and optionally one or more bacterial species selected from Lactobacillus acidophilus, Lactobacillus crispatus, Lactobacillus delbrueckii, Lactobacillus gasseri, Lactobacillus helveticus, Lactobacillus jensenii, Lactobacillus johnsonii, Lactobacillus rogosae, Lactobacillus thermophilus, LacticaseiBacillus casei, Ligilactobacillus salivarius, Limosilactobacillus fermentum, LacticaseiBacillus rhamnosus (previously Lactobacillus rhamnosus), Limosilactobacillus reuteri, Weissella viridescens, Bifidobacterium animalis, Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium choerinum, Bifidobacterium cuniculi, Bifidobacterium dentium, Bifidobacterium faecale, Bifidobacterium indicum, Bifidobacterium longum, Bifidobacterium magnum, Bifidobacterium pseudocatenulatum, Bifidobacterium pseudolongum, Bifidobacterium pullorum. In an embodiment the present invention provides a pharmaceutical composition comprising purified bacterial mixture of the genus Bacillus, bacterial species of Streptococcus selected from Streptococcus acidominimus, Streptococcus agalactiae, Streptococcus anginosus, Streptococcus avium, Streptococcus bovis, Streptococcus canis, Streptococcus caprae, Streptococcus caprinus, Streptococcus castoreus, Streptococcus caviae, Streptococcus cecorum, Streptococcus cremoris, Streptococcus criceti, Streptococcus dentisani, Streptococcus difficile, Streptococcus durans, Streptococcus dysgalactiae, Streptococcus entericus, Streptococcus epidermidis, Streptococcus equi, Streptococcus faecalis, Streptococcus faecium, Streptococcus ferus, Streptococcus gallinarum, Streptococcus gallolyticus, Streptococcus halotolerans, Streptococcus hansenii, Streptococcus hillyeri, Streptococcus himalayensis, Streptococcus hominis, Streptococcus humanilactis, Streptococcus hyointestinalis, Streptococcus hyovaginalis, Streptococcus ilei, Streptococcus infantis, Streptococcus intermedius, Streptococcus intestinalis, Streptococcus lactis, Streptococcus merionis, Streptococcus microaerophilica, Streptococcus mitis, Streptococcus morbillorum, Streptococcus moroccensis, Streptococcus mutans, Streptococcus oligofermentans, Streptococcus oralis, Streptococcus ovis, Streptococcus pacificus, Streptococcus panodentis, Streptococcus parasanguinis, Streptococcus parasanguis, Streptococcus parasuis, Streptococcus parauberis, Streptococcus parvulus, Streptococcus pasteurianus, Streptococcus peroris, Streptococcus plantarum, Streptococcus pyogenes, Streptococcus respiraculi, Streptococcus saccharolyticus, Streptococcus salivarius, Streptococcus saliviloxodontae, Streptococcus sanguinis, Streptococcus sciuri, Streptococcus sinensis, Streptococcus sobrinus, Streptococcus suis, Streptococcus thalassemiae, Streptococcus thermophilus, Streptococcus thoraltensis, Streptococcus uberis, Streptococcus urinalis, Streptococcus ursoris, Streptococcus vaginalis, Streptococcus varani, Streptococcus vestibularis, Streptococcus vicugnae, Streptococcus vulneris, Streptococcus waius, Streptococcus xiaochunlingii, Streptococcus zalophi, Peptostreptococcus anaerobius, Peptostreptococcus asaccharolyticus, Peptostreptococcus faecalis, Peptostreptococcus harei, Peptostreptococcus heliotrinreducens, Peptostreptococcus magnus, Peptostreptococcus octavius, Peptostreptococcus parvulus, Peptostreptococcus porci, Peptostreptococcus prevotii, Peptostreptococcus russellii, Peptostreptococcus stomatis, Peptostreptococcus tetradius, Peptostreptococcus vaginalis, Streptococcus anginosus subsp. anginosus, Streptococcus constellatus subsp. pharyngis, Streptococcus dysgalactiae subsp. dysgalactiae, Streptococcus equi subsp. equi, Streptococcus faecium subsp. casseliflavus, Streptococcus gallolyticus subsp. gallolyticus, Streptococcus halichoeri subsp. halichoeri, Streptococcus infantarius subsp. coli, Streptococcus infantarius subsp. infantarius, Streptococcus lactis subsp. cremoris, Streptococcus lactis subsp. lactis, Streptococcus mutans subsp. sobrinus, Streptococcus oralis subsp. oralis, Streptococcus phocae subsp. salmonis, Streptococcus salivarius subsp. Salivarius or Streptococcus salivarius subsp. Thermophilus and optionally one or more bacterial species selected from Lactobacillus acidophilus, Lactobacillus crispatus, Lactobacillus delbrueckii, Lactobacillus gasseri, Lactobacillus helveticus, Lactobacillus jensenii, Lactobacillus johnsonii, Lactobacillus rogosae, Lactobacillus thermophilus, Lacticaseibacillus casei, Ligilactobacillus salivarius, Limosilactobacillus fermentum, Lacticaseibacillus rhamnosus (previously Lactobacillus rhamnosus), Limosilactobacillus reuteri, Weissella viridescens, Bifidobacterium animalis, Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium choerinum, Bifidobacterium cuniculi, Bifidobacterium dentium, Bifidobacterium faecale, Bifidobacterium indicum, Bifidobacterium longum, Bifidobacterium magnum, Bifidobacterium pseudocatenulatum, Bifidobacterium pseudolongum, Bifidobacterium pullorum. In an embodiment the present invention provides a pharmaceutical composition comprising purified bacterial mixture of bacterial strains (bacterial species) from genus Bacillus selected from ZMT129, ZMT115, ZMT152, ZMT128, ZMT160, ZMT148, ZMT142 or ZMT122 and one or more bacterial strain from genus Streptococcus wherein the term ‘ZMT’ represents the internal codes. Bacterial strains and bacterial species may be used interchangeably here in the present invention. In an embodiment the present invention provides a pharmaceutical composition comprising purified bacterial mixture of one or more bacterial strains from genus Bacillus and bacterial strain from genus Streptococcus selected from ZMT114 or ZMT121. In an embodiment the present invention provides a pharmaceutical composition comprising purified bacterial mixture of the genus Bacillus selected from ZMT129, ZMT115, ZMT152, ZMT128, ZMT160, ZMT148, ZMT142 or ZMT122, one or more bacterial strain from genus Streptococcus selected from ZMT114 or ZMT121 and optionally one more bacterial strain selected from Lactobacillus acidophilus, Lactobacillus crispatus, Lactobacillus delbrueckii, Lactobacillus gasseri, Lactobacillus helveticus, Lactobacillus jensenii, Lactobacillus johnsonii, Lactobacillus rogosae, Lactobacillus thermophilus, Lacticaseibacillus casei, Ligilactobacillus salivarius, Limosilactobacillus fermentum, Lacticaseibacillus rhamnosus (previously Lactobacillus rhamnosus), Limosilactobacillus reuteri, Weissella viridescens, Bifidobacterium animalis, Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium choerinum, Bifidobacterium cuniculi, Bifidobacterium dentium, Bifidobacterium faecale, Bifidobacterium indicum, Bifidobacterium longum, Bifidobacterium magnum, Bifidobacterium pseudocatenulatum, Bifidobacterium pseudolongum, Bifidobacterium pullorum. In an embodiment the present invention provides a pharmaceutical composition comprising purified bacterial mixture of one or more bacterial strain from genus Bacillus selected from ZMT129, ZMT115, ZMT152, ZMT128, ZMT160, ZMT148, ZMT142 or ZMT122 and one or more bacterial strain from genus Streptococcus selected from ZMT114 or ZMT121 or both. In an embodiment the present invention provides a pharmaceutical composition comprising purified bacterial mixture of one or more bacterial strain from genus Bacillus selected from ZMT129, ZMT115, ZMT152, ZMT128, ZMT160, ZMT148, ZMT142 or ZMT122 and one or more bacterial strain from genus Streptococcus selected from ZMT114 or ZMT121 or both and optionally one more bacterial strain selected from ZMT141 or ZMT147 or both. In a preferred embodiment, the present invention provides a pharmaceutical composition comprising purified bacterial mixture of Bacillus subtilis and Streptococcus thermophilus. In a preferred embodiment, the present invention provides a pharmaceutical composition comprising purified bacterial mixture of Bacillus subtilis and Streptococcus thermophilus wherein Bacillus subtilis has an MTCC assigned number MTCC 25874 (ZMT129) and Streptococcus thermophilus has an MTCC assigned number MTCC 25871 (ZMT121). In a preferred embodiment, the present invention provides a pharmaceutical composition comprising purified bacterial mixture of Bacillus subtilis and Streptococcus thermophilus wherein Bacillus subtilis has an MTCC assigned number MTCC 25872 (ZMT122) and Streptococcus thermophilus has an MTCC assigned number MTCC 25871 (ZMT121). In one embodiment, the present invention provides a pharmaceutical composition comprising purified bacterial mixture of Bacillus subtilis and Streptococcus thermophilus wherein Bacillus subtilis has an MTCC assigned number MTCC 25873 (ZMT128) and Streptococcus thermophilus has an MTCC assigned number MTCC 25871 (ZMT121). In one embodiment, the present invention provides a pharmaceutical composition comprising purified bacterial mixture of Bacillus velezensis and Streptococcus thermophilus wherein Bacillus velezensis has an MTCC assigned number MTCC 25860 (ZMT148) and Streptococcus thermophilus has an MTCC assigned number MTCC 25871 (ZMT121). In one embodiment, the present invention provides a pharmaceutical composition comprising purified bacterial mixture of Bacillus velezensis and Streptococcus infantarius wherein Bacillus velezensis has an MTCC assigned number MTCC 25860 (ZMT148) and Streptococcus infantarius has an MTCC assigned number MTCC 25870 (ZMT114). In one embodiment, the present invention provides a pharmaceutical composition comprising purified bacterial mixture of Bacillus subtilis and Streptococcus infantarius wherein Bacillus subtilis has an MTCC assigned number MTCC 25872 (ZMT122) and Streptococcus infantarius has an MTCC assigned number MTCC 25870 (ZMT114). In one embodiment, the present invention provides a pharmaceutical composition comprising purified bacterial mixture of Bacillus subtilis and Streptococcus infantarius wherein Bacillus subtilis has an MTCC assigned number MTCC 25873 (ZMT128) and Streptococcus infantarius has an MTCC assigned number MTCC 25870 (ZMT114). In one embodiment, the present invention provides a pharmaceutical composition comprising purified bacterial mixture of Bacillus subtilis and Streptococcus infantarius wherein Bacillus subtilis has an MTCC assigned number MTCC 25874 (ZMT129) and Streptococcus infantarius has an MTCC assigned number MTCC 25870 (ZMT114). In one embodiment, the present invention provides a pharmaceutical composition comprising purified bacterial mixture of genus Bacillus and genus Streptococcus as embodied here in the present invention wherein the composition further comprises Enterobacter hormaechei having MTCC assigned number MTCC 25861 (ZMT141). In another embodiment, the present invention discloses a pharmaceutical composition comprising a purified bacterial mixture comprising two or more bacterial strains selected from the group consisting of genus Bacillus and genus Streptococcus. In another embodiment, the present invention discloses a pharmaceutical composition comprising a purified bacterial mixture comprising two or more bacterial strains selected from the group consisting of genus Bacillus, genus Streptococcus and genus selected from Lactobacillus, Leuconostoc, Lactococcus, Enterococcus, Weissella, Pediococcus, Aerococcus, Sporolactobacillus and Bifidobacterium. In some embodiments, the purified bacterial mixture comprises at least two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, or sixteen, bacterial strains selected from genus Bacillus and genus Streptococcus. In some embodiments, the purified bacterial mixture comprises at least two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, or sixteen, bacterial strains selected from genus Bacillus, genus Streptococcus and genus selected from Lactobacillus, Leuconostoc, Lactococcus, Enterococcus, Weissella, Pediococcus, Aerococcus, Sporolactobacillus and Bifidobacterium. In some embodiments, the present disclosure relates to methods for treating and / or preventing inflammatory and autoimmune disorders in a subject, the method comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a purified bacterial mixture comprising two or more bacterial strains selected from genus Bacillus, genus Streptococcus or suitable combination thereof. In some embodiments of the present disclosure relate to methods for treating and / or preventing inflammatory bowel disease (IBD) in a subject, the method comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a purified bacterial mixture comprising two or more bacterial strains selected from genus Bacillus, genus Streptococcus or suitable combination thereof. In some embodiments of the present disclosure relate to methods for treating and / or preventing UC in a subject, the method comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a purified bacterial mixture comprising two or more bacterial strains selected from genus Bacillus, genus Streptococcus or suitable combination thereof. In some embodiments of the present disclosure relate to methods for treating and / or preventing pouchitis in a subject, the method comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a purified bacterial mixture comprising two or more bacterial strains selected from genus Bacillus, genus Streptococcus or suitable combination thereof. In one of the embodiments, the present invention provides use of a pharmaceutical composition comprising a purified bacterial mixture comprising two or more bacterial strains selected from genus Bacillus, genus Streptococcus or suitable combination thereof for treating and / or preventing inflammatory and autoimmune disorders in a subject. In one of the embodiments, the present invention provides use of a pharmaceutical composition comprising a purified bacterial mixture comprising two or more bacterial strains selected from genus Bacillus, genus Streptococcus or suitable combination thereof as described elsewhere in the specification for treating and / or preventing inflammatory bowel disease (IBD) disorders in a subject. In one of the embodiments, the present invention provides use of a pharmaceutical composition comprising a purified bacterial mixture comprising two or more bacterial strains selected from genus Bacillus, genus Streptococcus or suitable combination thereof as described elsewhere in the specification for treating and / or preventing ulcerative colitis (UC) in a subject. In one of the embodiments, the present invention provides use of a pharmaceutical composition comprising a purified bacterial mixture comprising two or more bacterial strains selected from genus Bacillus, genus Streptococcus or suitable combination thereof as described elsewhere in the specification for treating and / or preventing pouchitis in a subject. In some embodiments, the bacterial strains of present invention are lyophilized. In some embodiments, the bacterial strains of present invention are spray-dried. In some embodiments, the bacterial strains of present invention are in spore form. In some embodiments, bacterial strains of present invention are in vegetative form. In some embodiments, bacterial strains of present invention are in heat killed form. In some embodiments, bacterial strains of present invention are in attenuated form. In some embodiments, the pharmaceutical composition is formulated for oral delivery. In some embodiments, the pharmaceutical composition is formulated for rectal delivery. In some embodiments, the pharmaceutical composition is formulated for delivery to the intestine. In some embodiments, the pharmaceutical composition is formulated for delivery to the colon. In some embodiments, the pharmaceutical composition is administered as a single dose. In some embodiments, the pharmaceutical composition is administered in multiple doses. In some embodiments, a dose of the pharmaceutical composition comprises between 103to 1013colony forming units (CFUs). In some embodiments, a dose of the pharmaceutical composition comprises between 105to 1012colony forming units (CFUs). In some embodiments, a dose of the pharmaceutical composition comprises about 103CFUs. In some embodiments, a dose of the pharmaceutical composition comprises about 104CFUs. In some embodiments, a dose of the pharmaceutical composition comprises about 105CFUs. In some embodiments, a dose of the pharmaceutical composition comprises about 106CFUs. In some embodiments, a dose of the pharmaceutical composition comprises about 107CFUs. In some embodiments, a dose of the pharmaceutical composition comprises about 108CFUs. In some embodiments, a dose of the pharmaceutical composition comprises about 109CFUs. In some embodiments, a dose of the pharmaceutical composition comprises about 1010CFUs. In some embodiments, a dose of the pharmaceutical composition comprises about 1011CFUs. In some embodiments, a dose of the pharmaceutical composition comprises about 1012CFUs. In some embodiments, a dose of the pharmaceutical composition comprises about 1013CFUs. In some embodiments, the multiple doses are administered on consecutive days. In some embodiments, the multiple doses are administered daily or one or more non- consecutive days up to six months as prescribed by a medical practitioner depending on the medical condition of the subject undergoing treatment. In some embodiments, the method further comprises administering an additional therapeutic agent such as immunotherapeutics, anti-angiogenic agents, cytokines, hormones, antibodies, polynucleotides, photodynamic therapeutic agents, non-steroid anti- inflammatory medications, antihistamines, alpha-adrenergic agonists, steroids, and any combination thereof to be co-administered with the pharmaceutical composition of the present invention. In a still further embodiment, the pharmaceutical composition may increase the amount of one or more short-chain fatty acids (SCFAs) in the subject. In some embodiments, the SCFA is 2- methyl butyric acid, acetic acid, butyric acid, hexanoic acid, isobutyric acid, isovaleric acid, propionic acid or valeric acid. In some embodiments, the pharmaceutical composition increases levels of short-chain fatty acids (SCFAs). In some embodiments, the pharmaceutical composition of the present invention may suppress one or more interleukins, preferably interleukin 8 (IL-8). In some of the other embodiments the composition is suitable for oral administration and formulated to survive gastric conditions and deliver viable bacteria to the intestine. In some embodiments, the pharmaceutical composition of the present invention may be administered alone or co-administered with other therapeutic agents such as immunotherapeutics, anti-angiogenic agents, cytokines, hormones, antibodies, polynucleotides, photodynamic therapeutic agents, non-steroid anti-inflammatory medications, antihistamines, alpha-adrenergic agonists, steroids, and any combination thereof. In one embodiment, the pharmaceutical composition of the present invention comprises mixture of bacterial strains from genus Bacillus and genus Streptococcus as embodied here in the specification and suitable excipients or suitable pharmaceutical carriers. In one embodiment, the present invention provides a combination of bacterial species from genus Bacillus and genus Streptococcus. In a preferred embodiment, the present invention provides the combination of bacterial species from genus Bacillus and species from genus Streptococcus, wherein species from genus Streptococcus is selected from Streptococcus acidominimus, Streptococcus agalactiae, Streptococcus anginosus, Streptococcus avium, Streptococcus bovis, Streptococcus canis, Streptococcus caprae, Streptococcus caprinus, Streptococcus castoreus, Streptococcus caviae, Streptococcus cecorum, Streptococcus cremoris, Streptococcus criceti, Streptococcus dentisani, Streptococcus difficile, Streptococcus durans, Streptococcus dysgalactiae, Streptococcus entericus, Streptococcus epidermidis, Streptococcus equi, Streptococcus faecalis, Streptococcus faecium, Streptococcus ferus, Streptococcus gallinarum, Streptococcus gallolyticus, Streptococcus halotolerans, Streptococcus hansenii, Streptococcus hillyeri, Streptococcus himalayensis, Streptococcus hominis, Streptococcus humanilactis, Streptococcus hyointestinalis, Streptococcus hyovaginalis, Streptococcus ilei, Streptococcus infantis, Streptococcus intermedius, Streptococcus intestinalis, Streptococcus lactis, Streptococcus merionis, Streptococcus microaerophilica, Streptococcus mitis, Streptococcus morbillorum, Streptococcus moroccensis, Streptococcus mutans, Streptococcus oligofermentans, Streptococcus oralis, Streptococcus ovis, Streptococcus pacificus, Streptococcus panodentis, Streptococcus parasanguinis, Streptococcus parasanguis, Streptococcus parasuis, Streptococcus parauberis, Streptococcus parvulus, Streptococcus pasteurianus, Streptococcus peroris, Streptococcus plantarum, Streptococcus pyogenes, Streptococcus respiraculi, Streptococcus saccharolyticus, Streptococcus salivarius, Streptococcus saliviloxodontae, Streptococcus sanguinis, Streptococcus sciuri, Streptococcus sinensis, Streptococcus sobrinus, Streptococcus suis, Streptococcus thalassemiae, Streptococcus thermophilus, Streptococcus thoraltensis, Streptococcus uberis, Streptococcus urinalis, Streptococcus ursoris, Streptococcus vaginalis, Streptococcus varani, Streptococcus vestibularis, Streptococcus vicugnae, Streptococcus vulneris, Streptococcus waius, Streptococcus xiaochunlingii, Streptococcus zalophi, PeptoStreptococcus anaerobius, PeptoStreptococcus asaccharolyticus, PeptoStreptococcus faecalis, PeptoStreptococcus harei, PeptoStreptococcus heliotrinreducens, PeptoStreptococcus magnus, PeptoStreptococcus octavius, PeptoStreptococcus parvulus, PeptoStreptococcus porci, PeptoStreptococcus prevotii, PeptoStreptococcus russellii, PeptoStreptococcus stomatis, PeptoStreptococcus tetradius, PeptoStreptococcus vaginalis, Streptococcus anginosus subsp. anginosus, Streptococcus constellatus subsp. pharyngis, Streptococcus dysgalactiae subsp. dysgalactiae, Streptococcus equi subsp. equi, Streptococcus faecium subsp. casseliflavus, Streptococcus gallolyticus subsp. gallolyticus, Streptococcus halichoeri subsp. halichoeri, Streptococcus infantarius subsp. coli, Streptococcus infantarius, Streptococcus lactis subsp. cremoris, Streptococcus lactis subsp. lactis, Streptococcus mutans subsp. sobrinus, Streptococcus oralis subsp. oralis, Streptococcus phocae subsp. salmonis, Streptococcus salivarius subsp. Salivarius or Streptococcus salivarius subsp. Thermophilus. In a preferred embodiment, the present invention provides the combination of bacterial species from genus Streptococcus and species from genus Bacillus wherein species from genus Bacillus is selected from Bacillus acidocaldarius, Bacillus amyloliquefaciens, Bacillus amylolyticus, Bacillus anthracis, Bacillus aryabhattai , Bacillus cereus, Bacillus fusiformis, Bacillus globisporus, Bacillus hominis , Bacillus infantis, Bacillus insolitus, Bacillus larvae, Bacillus laterosporus, Bacillus lentimorbus, Bacillus lentus, Bacillus licheniformis, Bacillus macerans, Bacillus macquariensis, Bacillus megaterium, Bacillus mesophilus, Bacillus methylotrophicus, Bacillus multiformis, Bacillus mycoides, Bacillus oceani, Bacillus pantothenticus, Bacillus paralicheniformis, Bacillus paramycoides, Bacillus pasteurii, Bacillus perfringens, Bacillus polyfermenticus, Bacillus polymyxa, Bacillus popilliae, Bacillus pumilus, Bacillus pyogenes, Bacillus sanguinis, Bacillus siamensis, Bacillus spizizenii, Bacillus sporogenes, Bacillus stearothermophilus, Bacillus subtilis, Bacillus tequilensis, Bacillus thermoaerophilus, Bacillus thermodenitrificans, Bacillus thermolactis, Bacillus thermophilus, Bacillus thermotolerans, Bacillus thetaiotaomicron, Bacillus thuringiensis and Bacillus velezensis. In a preferred embodiment, the present invention provides the combination of bacterial species from genus Bacillus and genus Streptococcus wherein species of genus Bacillus are selected from Bacillus acidocaldarius, Bacillus amyloliquefaciens, Bacillus amylolyticus, Bacillus anthracis, Bacillus aryabhattai , Bacillus cereus, Bacillus fusiformis, Bacillus globisporus, Bacillus hominis , Bacillus infantis, Bacillus insolitus, Bacillus larvae, Bacillus laterosporus, Bacillus lentimorbus, Bacillus lentus, Bacillus licheniformis, Bacillus macerans, Bacillus macquariensis, Bacillus megaterium, Bacillus mesophilus, Bacillus methylotrophicus, Bacillus multiformis, Bacillus mycoides, Bacillus oceani, Bacillus pantothenticus, Bacillus paralicheniformis, Bacillus paramycoides, Bacillus pasteurii, Bacillus perfringens, Bacillus polyfermenticus, Bacillus polymyxa, Bacillus popilliae, Bacillus pumilus, Bacillus pyogenes, Bacillus sanguinis, Bacillus siamensis, Bacillus spizizenii, Bacillus sporogenes, Bacillus stearothermophilus, Bacillus subtilis, Bacillus tequilensis, Bacillus thermoaerophilus, Bacillus thermodenitrificans, Bacillus thermolactis, Bacillus thermophilus, Bacillus thermotolerans, Bacillus thetaiotaomicron, Bacillus thuringiensis and Bacillus velezensis and species of genus Streptococcus are selected from Streptococcus acidominimus, Streptococcus agalactiae, Streptococcus anginosus, Streptococcus avium, Streptococcus bovis, Streptococcus canis, Streptococcus caprae, Streptococcus caprinus, Streptococcus castoreus, Streptococcus caviae, Streptococcus cecorum, Streptococcus cremoris, Streptococcus criceti, Streptococcus dentisani, Streptococcus difficile, Streptococcus durans, Streptococcus dysgalactiae, Streptococcus entericus, Streptococcus epidermidis, Streptococcus equi, Streptococcus faecalis, Streptococcus faecium, Streptococcus ferus, Streptococcus gallinarum, Streptococcus gallolyticus, Streptococcus halotolerans, Streptococcus hansenii, Streptococcus hillyeri, Streptococcus himalayensis, Streptococcus hominis, Streptococcus humanilactis, Streptococcus hyointestinalis, Streptococcus hyovaginalis, Streptococcus ilei, Streptococcus infantis, Streptococcus intermedius, Streptococcus intestinalis, Streptococcus lactis, Streptococcus merionis, Streptococcus microaerophilica, Streptococcus mitis, Streptococcus morbillorum, Streptococcus moroccensis, Streptococcus mutans, Streptococcus oligofermentans, Streptococcus oralis, Streptococcus ovis, Streptococcus pacificus, Streptococcus panodentis, Streptococcus parasanguinis, Streptococcus parasanguis, Streptococcus parasuis, Streptococcus parauberis, Streptococcus parvulus, Streptococcus pasteurianus, Streptococcus peroris, Streptococcus plantarum, Streptococcus pyogenes, Streptococcus respiraculi, Streptococcus saccharolyticus, Streptococcus salivarius, Streptococcus saliviloxodontae, Streptococcus sanguinis, Streptococcus sciuri, Streptococcus sinensis, Streptococcus sobrinus, Streptococcus suis, Streptococcus thalassemiae, Streptococcus thermophilus, Streptococcus thoraltensis, Streptococcus uberis, Streptococcus urinalis, Streptococcus ursoris, Streptococcus vaginalis, Streptococcus varani, Streptococcus vestibularis, Streptococcus vicugnae, Streptococcus vulneris, Streptococcus waius, Streptococcus xiaochunlingii, Streptococcus zalophi, PeptoStreptococcus anaerobius, PeptoStreptococcus asaccharolyticus, PeptoStreptococcus faecalis, PeptoStreptococcus harei, PeptoStreptococcus heliotrinreducens, PeptoStreptococcus magnus, PeptoStreptococcus octavius, PeptoStreptococcus parvulus, PeptoStreptococcus porci, PeptoStreptococcus prevotii, PeptoStreptococcus russellii, PeptoStreptococcus stomatis, PeptoStreptococcus tetradius, PeptoStreptococcus vaginalis, Streptococcus anginosus subsp. anginosus, Streptococcus constellatus subsp. pharyngis, Streptococcus dysgalactiae subsp. dysgalactiae, Streptococcus equi subsp. equi, Streptococcus faecium subsp. casseliflavus, Streptococcus gallolyticus subsp. gallolyticus, Streptococcus halichoeri subsp. halichoeri, Streptococcus infantarius subsp. coli, Streptococcus infantarius, Streptococcus lactis subsp. cremoris, Streptococcus lactis subsp. lactis, Streptococcus mutans subsp. sobrinus, Streptococcus oralis subsp. oralis, Streptococcus phocae subsp. salmonis, Streptococcus salivarius subsp. Salivarius or Streptococcus salivarius subsp. Thermophilus. In a preferred embodiment, the present invention provides the combination of bacterial species from genus Bacillus is Bacillus subtilis having MTCC assigned number MTCC 25872 (ZMT122) or MTCC 25873 (ZMT128) or MTCC 25874 (ZMT129) and genus Streptococcus wherein species of genus Streptococcus are selected from Streptococcus acidominimus, Streptococcus agalactiae, Streptococcus anginosus, Streptococcus avium, Streptococcus bovis, Streptococcus canis, Streptococcus caprae, Streptococcus caprinus, Streptococcus castoreus, Streptococcus caviae, Streptococcus cecorum, Streptococcus cremoris, Streptococcus criceti, Streptococcus dentisani, Streptococcus difficile, Streptococcus durans, Streptococcus dysgalactiae, Streptococcus entericus, Streptococcus epidermidis, Streptococcus equi, Streptococcus faecalis, Streptococcus faecium, Streptococcus ferus, Streptococcus gallinarum, Streptococcus gallolyticus, Streptococcus halotolerans, Streptococcus hansenii, Streptococcus hillyeri, Streptococcus himalayensis, Streptococcus hominis, Streptococcus humanilactis, Streptococcus hyointestinalis, Streptococcus hyovaginalis, Streptococcus ilei, Streptococcus infantis, Streptococcus intermedius, Streptococcus intestinalis, Streptococcus lactis, Streptococcus merionis, Streptococcus microaerophilica, Streptococcus mitis, Streptococcus morbillorum, Streptococcus moroccensis, Streptococcus mutans, Streptococcus oligofermentans, Streptococcus oralis, Streptococcus ovis, Streptococcus pacificus, Streptococcus panodentis, Streptococcus parasanguinis, Streptococcus parasanguis, Streptococcus parasuis, Streptococcus parauberis, Streptococcus parvulus, Streptococcus pasteurianus, Streptococcus peroris, Streptococcus plantarum, Streptococcus pyogenes, Streptococcus respiraculi, Streptococcus saccharolyticus, Streptococcus salivarius, Streptococcus saliviloxodontae, Streptococcus sanguinis, Streptococcus sciuri, Streptococcus sinensis, Streptococcus sobrinus, Streptococcus suis, Streptococcus thalassemiae, Streptococcus thermophilus, Streptococcus thoraltensis, Streptococcus uberis, Streptococcus urinalis, Streptococcus ursoris, Streptococcus vaginalis, Streptococcus varani, Streptococcus vestibularis, Streptococcus vicugnae, Streptococcus vulneris, Streptococcus waius, Streptococcus xiaochunlingii, Streptococcus zalophi, PeptoStreptococcus anaerobius, PeptoStreptococcus asaccharolyticus, PeptoStreptococcus faecalis, PeptoStreptococcus harei, PeptoStreptococcus heliotrinreducens, PeptoStreptococcus magnus, PeptoStreptococcus octavius, PeptoStreptococcus parvulus, PeptoStreptococcus porci, PeptoStreptococcus prevotii, PeptoStreptococcus russellii, PeptoStreptococcus stomatis, PeptoStreptococcus tetradius, PeptoStreptococcus vaginalis, Streptococcus anginosus subsp. anginosus, Streptococcus constellatus subsp. pharyngis, Streptococcus dysgalactiae subsp. dysgalactiae, Streptococcus equi subsp. equi, Streptococcus faecium subsp. casseliflavus, Streptococcus gallolyticus subsp. gallolyticus, Streptococcus halichoeri subsp. halichoeri, Streptococcus infantarius subsp. coli, Streptococcus infantarius, Streptococcus lactis subsp. cremoris, Streptococcus lactis subsp. lactis, Streptococcus mutans subsp. sobrinus, Streptococcus oralis subsp. oralis, Streptococcus phocae subsp. salmonis, Streptococcus salivarius subsp. Salivarius or Streptococcus salivarius subsp. Thermophilus. In a preferred embodiment, the present invention provides the combination of bacterial species from genus Bacillus is Bacillus velezensis having MTCC assigned number MTCC 25860 (ZMT148), and bacterial species of genus Streptococcus selected from Streptococcus acidominimus, Streptococcus agalactiae, Streptococcus anginosus, Streptococcus avium, Streptococcus bovis, Streptococcus canis, Streptococcus caprae, Streptococcus caprinus, Streptococcus castoreus, Streptococcus caviae, Streptococcus cecorum, Streptococcus cremoris, Streptococcus criceti, Streptococcus dentisani, Streptococcus difficile, Streptococcus durans, Streptococcus dysgalactiae, Streptococcus entericus, Streptococcus epidermidis, Streptococcus equi, Streptococcus faecalis, Streptococcus faecium, Streptococcus ferus, Streptococcus gallinarum, Streptococcus gallolyticus, Streptococcus halotolerans, Streptococcus hansenii, Streptococcus hillyeri, Streptococcus himalayensis, Streptococcus hominis, Streptococcus humanilactis, Streptococcus hyointestinalis, Streptococcus hyovaginalis, Streptococcus ilei, Streptococcus infantis, Streptococcus intermedius, Streptococcus intestinalis, Streptococcus lactis, Streptococcus merionis, Streptococcus microaerophilica, Streptococcus mitis, Streptococcus morbillorum, Streptococcus moroccensis, Streptococcus mutans, Streptococcus oligofermentans, Streptococcus oralis, Streptococcus ovis, Streptococcus pacificus, Streptococcus panodentis, Streptococcus parasanguinis, Streptococcus parasanguis, Streptococcus parasuis, Streptococcus parauberis, Streptococcus parvulus, Streptococcus pasteurianus, Streptococcus peroris, Streptococcus plantarum, Streptococcus pyogenes, Streptococcus respiraculi, Streptococcus saccharolyticus, Streptococcus salivarius, Streptococcus saliviloxodontae, Streptococcus sanguinis, Streptococcus sciuri, Streptococcus sinensis, Streptococcus sobrinus, Streptococcus suis, Streptococcus thalassemiae, Streptococcus thermophilus, Streptococcus thoraltensis, Streptococcus uberis, Streptococcus urinalis, Streptococcus ursoris, Streptococcus vaginalis, Streptococcus varani, Streptococcus vestibularis, Streptococcus vicugnae, Streptococcus vulneris, Streptococcus waius, Streptococcus xiaochunlingii, Streptococcus zalophi, PeptoStreptococcus anaerobius, PeptoStreptococcus asaccharolyticus, PeptoStreptococcus faecalis, PeptoStreptococcus harei, PeptoStreptococcus heliotrinreducens, PeptoStreptococcus magnus, PeptoStreptococcus octavius, PeptoStreptococcus parvulus, PeptoStreptococcus porci, PeptoStreptococcus prevotii, PeptoStreptococcus russellii, PeptoStreptococcus stomatis, PeptoStreptococcus tetradius, PeptoStreptococcus vaginalis, Streptococcus anginosus subsp. anginosus, Streptococcus constellatus subsp. pharyngis, Streptococcus dysgalactiae subsp. dysgalactiae, Streptococcus equi subsp. equi, Streptococcus faecium subsp. casseliflavus, Streptococcus gallolyticus subsp. gallolyticus, Streptococcus halichoeri subsp. halichoeri, Streptococcus infantarius subsp. coli, Streptococcus infantarius, Streptococcus lactis subsp. cremoris, Streptococcus lactis subsp. lactis, Streptococcus mutans subsp. sobrinus, Streptococcus oralis subsp. oralis, Streptococcus phocae subsp. salmonis, Streptococcus salivarius subsp. Salivarius or Streptococcus salivarius subsp. Thermophilus. In a preferred embodiment, the present invention provides the combination of bacterial species from genus Streptococcus is Streptococcus thermophilus having MTCC number MTCC 25871 (ZMT121) and bacterial species of genus Bacillus selected Bacillus acidocaldarius, Bacillus amyloliquefaciens, Bacillus amylolyticus, Bacillus anthracis, Bacillus aryabhattai , Bacillus cereus, Bacillus fusiformis, Bacillus globisporus, Bacillus hominis , Bacillus infantis, Bacillus insolitus, Bacillus larvae, Bacillus laterosporus, Bacillus lentimorbus, Bacillus lentus, Bacillus licheniformis, Bacillus macerans, Bacillus macquariensis, Bacillus megaterium, Bacillus mesophilus, Bacillus methylotrophicus, Bacillus multiformis, Bacillus mycoides, Bacillus oceani, Bacillus pantothenticus, Bacillus paralicheniformis, Bacillus paramycoides, Bacillus pasteurii, Bacillus perfringens, Bacillus polyfermenticus, Bacillus polymyxa, Bacillus popilliae, Bacillus pumilus, Bacillus pyogenes, Bacillus sanguinis, Bacillus siamensis, Bacillus spizizenii, Bacillus sporogenes, Bacillus stearothermophilus, Bacillus subtilis, Bacillus tequilensis, Bacillus thermoaerophilus, Bacillus thermodenitrificans, Bacillus thermolactis, Bacillus thermophilus, Bacillus thermotolerans, Bacillus thetaiotaomicron, Bacillus thuringiensis and Bacillus velezensis In a preferred embodiment, the present invention provides the combination of bacterial species from genus Streptococcus is Streptococcus infantarius having MTCC assigned number MTCC 25870 (ZMT114), and bacterial species of genus Bacillus selected from Bacillus acidocaldarius, Bacillus amyloliquefaciens, Bacillus amylolyticus, Bacillus anthracis, Bacillus aryabhattai , Bacillus cereus, Bacillus fusiformis, Bacillus globisporus, Bacillus hominis , Bacillus infantis, Bacillus insolitus, Bacillus larvae, Bacillus laterosporus, Bacillus lentimorbus, Bacillus lentus, Bacillus licheniformis, Bacillus macerans, Bacillus macquariensis, Bacillus megaterium, Bacillus mesophilus, Bacillus methylotrophicus, Bacillus multiformis, Bacillus mycoides, Bacillus oceani, Bacillus pantothenticus, Bacillus paralicheniformis, Bacillus paramycoides, Bacillus pasteurii, Bacillus perfringens, Bacillus polyfermenticus, Bacillus polymyxa, Bacillus popilliae, Bacillus pumilus, Bacillus pyogenes, Bacillus sanguinis, Bacillus siamensis, Bacillus spizizenii, Bacillus sporogenes, Bacillus stearothermophilus, Bacillus subtilis, Bacillus tequilensis, Bacillus thermoaerophilus, Bacillus thermodenitrificans, Bacillus thermolactis, Bacillus thermophilus, Bacillus thermotolerans, Bacillus thetaiotaomicron, Bacillus thuringiensis and Bacillus velezensis In a preferred embodiment, the present invention provides the combination of bacterial species from genus Bacillus is Bacillus subtilis or Bacillus velezensis and bacterial species from genus Streptococcus is Streptococcus thermophilus or Streptococcus infantarius and suitable combinations thereof. In a preferred embodiment, the present invention provides the combination of bacterial species from genus Bacillus is Bacillus subtilis has a MTCC number selected from MTCC 25872 (ZMT122), MTCC 25873 (ZMT128) and MTCC 25874 (ZMT129) and species from genus Streptococcus as disclosed elsewhere in the specification. In a preferred embodiment, the present invention provides the combination of bacterial species from genus Streptococcus is Streptococcus thermophilus has a MTCC assigned number MTCC assigned number MTCC 25871 (ZMT121) and species from genus Bacillus as disclosed elsewhere in the specification. In a preferred embodiment, the present invention provides the combination of purified bacterial mixture of Bacillus subtilis and Streptococcus thermophilus wherein Bacillus subtilis has an MTCC assigned number MTCC 25874 (ZMT129) and Streptococcus thermophilus has an MTCC assigned number MTCC 25871 (ZMT121). In a preferred embodiment, the present invention provides the combination of bacterial species comprising purified bacterial mixture of Bacillus subtilis and Streptococcus thermophilus wherein Bacillus subtilis has an MTCC assigned number MTCC 25872 (ZMT122) and Streptococcus thermophilus has an MTCC assigned number MTCC 25871 (ZMT121). In a preferred embodiment, the present invention provides the combination of bacterial species comprising purified bacterial mixture of Bacillus subtilis and Streptococcus thermophilus wherein Bacillus subtilis has an MTCC assigned number MTCC 25873 (ZMT128) and Streptococcus thermophilus has an MTCC assigned number MTCC 25871 (ZMT121). In a preferred embodiment, the present invention provides the combination of bacterial species comprising purified bacterial mixture of Bacillus velezensis and Streptococcus thermophilus wherein Bacillus velezensis has an MTCC assigned number MTCC 25860 (ZMT148) and Streptococcus thermophilus has an MTCC assigned number MTCC 25871 (ZMT121). In a preferred embodiment, the present invention provides the combination of bacterial species comprising purified bacterial mixture of Bacillus velezensis and Streptococcus infantarius wherein Bacillus velezensis has an MTCC assigned number MTCC 25860 (ZMT148) and Streptococcus infantarius has an MTCC assigned number MTCC 25870 (ZMT114). In a preferred embodiment, the present invention provides the combination of bacterial species comprising purified bacterial mixture of Bacillus subtilis and Streptococcus infantarius wherein Bacillus subtilis has an MTCC assigned number MTCC 25872 (ZMT122) and Streptococcus infantarius has an MTCC assigned number MTCC 25870 (ZMT114). In a preferred embodiment, the present invention provides the combination of bacterial species comprising purified bacterial mixture of Bacillus subtilis and Streptococcus infantarius wherein Bacillus subtilis has an MTCC assigned number MTCC 25873 (ZMT128) and Streptococcus infantarius has an MTCC assigned number MTCC 25870 (ZMT114). In a preferred embodiment, the present invention provides the combination of bacterial species comprising purified bacterial mixture of Bacillus subtilis and Streptococcus infantarius wherein Bacillus subtilis has an MTCC assigned number MTCC 25874 (ZMT129) and Streptococcus infantarius has an MTCC assigned number MTCC 25870 (ZMT114). In a preferred embodiment, the present invention provides the combination of bacterial species from genus Bacillus and species from genus Streptococcus as disclosed elsewhere in the specification, further comprises Enterobacter hormaechei having MTCC assigned number MTCC 25861 (ZMT141). In a preferred embodiment, the present invention provides the pharmaceutical composition comprising combination of bacterial species from genus Bacillus and genus Streptococcus as disclosed elsewhere in the specification, wherein a dose of the pharmaceutical composition comprises between 103to 1013colony forming units (CFUs), preferably between 105to 1012colony forming units (CFUs). In a preferred embodiment, the present invention provides a method for treating and / or preventing inflammatory bowel disease (IBD), ulcerative colitis (UC) and / or pouchitis in a subject, wherein the method comprising administering to the subject a therapeutically effective amount of combination of species from genus Bacillus and species from genus Streptococcus as disclosed elsewhere in the specification. In a preferred embodiment, the present invention provides use of the combination of species from genus Bacillus and species from genus Streptococcus as disclosed elsewhere in the specification in treating and / or preventing inflammatory bowel disease (IBD), ulcerative colitis (UC) and / or pouchitis in a subject. The above and other embodiments of the present invention are disclosed further hereinafter. Abbreviations: BHIA: Brain Heart Infusion agar EA: Elliker’s agar h or hrs: Hours HBA: HiCrome Bacillus agar LBA: Luria Bertani agar min: Minutes MTCC: Microbial Type Culture Collection NA: Nutrient agar OD: Optical density PBS: Phosphate buffer saline SCDA: Soyabean Casein Digest Agar TSA: Tryptic soy Agar DETAILED DESCRIPTION OF THE INVENTION The present invention provides pharmaceutical composition of isolated bacteria from genus Bacillus and genus Streptococcus. The composition comprises combination of bacterial strains from genus Bacillus and genus Streptococcus. The composition may further optionally comprise bacterial strain from the genus other than Bacillus and Streptococcus. The genus other than Bacillus and Streptococcus can be aerobic or anaerobic or both. This includes, but is not limited to genus selected from Lactobacillus, Leuconostoc, Lactococcus, Enterococcus, Weissella, Pediococcus, Aerococcus, Sporolactobacillus and Bifidobacterium. The bacterial strain(s) of the present invention are deposited in microbial type culture collection (MTCC) Chandigarh. The MTCC number assigned to the deposited bacterial strains are as below; ZMT culture ID MTCC number Culture identity ZMT148 MTCC 25860 Bacillus velezensis ZMT141 MTCC 25861 Enterobacter hormaechei ZMT114 MTCC 25870 Streptococcus infantarius ZMT122 MTCC 25872 Bacillus subtilis ZMT128 MTCC 25873 Bacillus subtilis ZMT129 MTCC 25874 Bacillus subtilis ZMT121 MTCC 25871 Streptococcus thermophilus ZMT116 Not available Bacillus subtilis The ZMT culture ID is an in-house code created by an applicant to determine bacterial strain. E.g. ZMT148 is an in-house code created which corresponds to bacterial strain Bacillus velezensis. The MTCC assigned number for the said strain is MTCC 25860. Therefore, it is depicted as ZMT148 which corresponds to MTCC 25860. The other bacterial strains of the present invention can be also identified in same manner. The composition of the present invention provides one or more bacterial strains from genus Bacillus and genus Streptococcus wherein the bacterial strain of genus Bacillus is selected from Table 1 as mentioned herein below and bacterial strain of genus Streptococcus is selected from Table 2 as mentioned herein below; Table 1 Name of Bacillus Name of Bacillus Name of Bacillus species species species Bacillus abyssalis Bacillus cibi Bacillus jeddahensis Bacillus acanthi Bacillus crassostreae Bacillus jeotgali Bacillus acidiceler Bacillus crescens Bacillus kaustophilus Bacillus acidicola Bacillus daliensis Bacillus kexueae Bacillus acidinfaciens Bacillus daqingensis Bacillus kiskunsagensis Bacillus acidiproducens Bacillus decisifrondis Bacillus kobensis Bacillus aciditolerans Bacillus dicomae Bacillus lacisalsi Bacillus acidocaldarius Bacillus dipsosauri Bacillus lacus Bacillus aerophilus Bacillus ectoiniformans Bacillus laevolacticus Bacillus aestuarii Bacillus edaphicus Bacillus larvae Bacillus agaradhaerens Bacillus ehimensis Bacillus laterosporus Bacillus agri Bacillus eiseniae Bacillus lautus Bacillus aidingensis Bacillus formosus Bacillus lehensis Bacillus akibai Bacillus fumarioli Bacillus lentimorbus Bacillus albus Bacillus fungorum Bacillus lentus Bacillus alcalophilus Bacillus fusiformis Bacillus licheniformis Bacillus algicola Bacillus gaemokensis Bacillus ligniniphilus Bacillus alkalilacus Bacillus galactophilus Bacillus lindianensis Bacillus alkalinitrilicus Bacillus galactosidilytic Bacillus litoralis us Bacillus alkalisediminis Bacillus galliciensis Bacillus litorisediminis Bacillus alkalitelluris Bacillus gelatini Bacillus macerans Bacillus alvei Bacillus gibsonii Bacillus macquariensis Bacillus amyloliquefacie Bacillus globisporus Bacillus mangrovi ns Bacillus amylolyticus Bacillus gossypii Bacillus manliponensis Bacillus andreesenii Bacillus graminis Bacillus mannanilyticus Bacillus anthracis Bacillus halmapalus Bacillus manusensis Bacillus antri Bacillus haloalkaliphilus Bacillus marinisediment orum Bacillus aquiflavi Bacillus halochares Bacillus megaterium Bacillus aquimaris Bacillus halodenitrifican Bacillus mesonae s Bacillus arachidis Bacillus halodurans Bacillus mesophilus Bacillus arenosi Bacillus halophilus Bacillus methanolicus Bacillus arseniciselenati Bacillus halosaccharovo Bacillus methylotrophicu s rans s Bacillus arsenicus Bacillus halotolerans Bacillus mexicanus Bacillus arvi Bacillus haynesii Bacillus migulanus Bacillus aryabhattai Bacillus hisashii Bacillus miscanthi Bacillus asahii Bacillus hominis Bacillus mobilis Bacillus atrophaeus Bacillus horikoshii Bacillus mojavensis Bacillus campisalis Bacillus humi Bacillus mucilaginosus Bacillus caseinilyticus Bacillus inaquosorum Bacillus multiformis Bacillus catenulatus Bacillus indicus Bacillus muralis Bacillus cellulosilyticus Bacillus infantis Bacillus murimartini . Bacillus centrosporus Bacillus infernus Bacillus mycoides Bacillus cereus Bacillus insolitus Bacillus naganoensis Bacillus chondroitinus Bacillus invictae Bacillus nakamurai Bacillus choshinensis Bacillus iocasae Bacillus niacini Name of Bacillus Name of Bacillus Name of Bacillus species species species Bacillus chungangensis Bacillus iranensis Bacillus nitratireducens Bacillus novalis Bacillus salarius Bacillus thermoleovoran s Bacillus oceani Bacillus salexigens Bacillus thermophilus Bacillus oceanisedimini Bacillus salidurans Bacillus thermoruber s Bacillus odysseyi Bacillus salinus Bacillus thermotolerans Bacillus okhensis Bacillus saliphilus Bacillus thetaiotaomicro n Bacillus pallidus Bacillus salitolerans Bacillus thiaminolyticus Bacillus panacisoli Bacillus salsus Bacillus thioparus Bacillus panaciterrae Bacillus sanguinis Bacillus thuringiensis Bacillus pantothenticus Bacillus scatologenes Bacillus tianshenii Bacillus parabrevis Bacillus schlegelii Bacillus toyonensis Bacillus paraflexus Bacillus sedimini. Bacillus tropicus Bacillus paralichenifor Bacillus selenatarsenatis Bacillus trypoxylicola mis Bacillus paramycoides Bacillus seohaeanensis Bacillus urbisdiaboli Bacillus paranthracis Bacillus siamensis Bacillus urumqiensis Bacillus pasteurii Bacillus simplex Bacillus validus Bacillus patagoniensis Bacillus sinesaloumensis Bacillus vallismortis Bacillus peoriae Bacillus notoginsengisoli Bacillus vedderi Bacillus perfringens Bacillus smithii Bacillus velezensis Bacillus persepolensis Bacillus solani Bacillus vietnamensis Bacillus persicus Bacillus soli Bacillus vini Bacillus pervagus Bacillus solimangrovi Bacillus vireti Bacillus polyfermenticus Bacillus solisalsi Bacillus vulcani Bacillus polygoni Bacillus spizizenii Bacillus wakoensis Bacillus polymyxa Bacillus spongiae Bacillus weihenstephane nsis Bacillus popilliae "Bacillus sporogenes" Bacillus wiedmannii Bacillus populi Bacillus stamsii Bacillus wudalianchiensi s Bacillus praedii Bacillus stearothermophi Bacillus wuyishanensis lus Bacillus pseudofirmus Bacillus stercoris Bacillus xiamenensis Bacillus psychrodurans Bacillus suaedae Bacillus xiaoxiensis Bacillus psychrophilus Bacillus subterraneus Bacillus xiapuensis Bacillus pulvifaciens Bacillus subtilis Bacillus zeae Bacillus pumilus Bacillus swezeyi Bacillus zhangzhouensis Bacillus purgationiresist Bacillus taeanensis Bacillus zhanjiangensis ans Bacillus pycnus Bacillus taiwanensis Bacillus salacetis Bacillus pyogenes Bacillus tamaricis Bacillus thermolactis Bacillus qingdaonensis Bacillus tepidiphilus Bacillus qingshengii Bacillus tequilensis Bacillus reuszeri Bacillus thermoaerophil us Bacillus rhizoplanae Bacillus thermoamylovor ans Bacillus rhizosphaerae Bacillus thermoantarctic us Bacillus rigiliprofundi Bacillus thermocatenulat us Bacillus rigui Bacillus thermocloaceae Bacillus ruris Bacillus thermocopriae Bacillus safensis Bacillus thermodenitrific ans Bacillus saganii Bacillus thermoglucosid asius Table 2 Name of Name of Streptococcus Name of Streptococcus Streptococcus species species species Streptococcus acido Streptococcus ovis Peptostreptococcus stomatis minimus Streptococcus agala Streptococcus pacificus Peptostreptococcus tetradius ctiae Streptococcus angin Streptococcus panodent Peptostreptococcus vaginalis osus is Streptococcus aviu Streptococcus parasang Streptococcus anginosus subs m uinis p. anginosus Streptococcus bovis Streptococcus parasang Streptococcus constellatus sub uis sp. pharyngis Streptococcus canis Streptococcus parasuis Streptococcus dysgalactiae su bsp. dysgalactiae Streptococcus capr Streptococcus parauber Streptococcus equi subsp. equ ae is i Streptococcus capri Streptococcus parvulus Streptococcus faecium subsp. nus casseliflavus Streptococcus casto Streptococcus pasteuria Streptococcus gallolyticus sub reus nus sp. gallolyticus Streptococcus cavia Streptococcus peroris Streptococcus halichoeri subs e p. halichoeri" Streptococcus cecor Streptococcus plantaru Streptococcus infantarius subs um m p. coli Streptococcus crem Streptococcus pyogenes Streptococcus infantarius subs oris p. infantarius Streptococcus cricet Streptococcus respiracu Streptococcus lactis subsp. cr i li emoris Streptococcus denti Streptococcus saccharol Streptococcus lactis subsp. lac sani yticus tis Streptococcus diffic Streptococcus salivarius Streptococcus mutans subsp. s ile obrinus Streptococcus dura Streptococcus saliviloxo Streptococcus oralis subsp. or ns dontae alis Streptococcus dysg Streptococcus sanguinis Streptococcus phocae subsp. s alactiae almonis Streptococcus enter Streptococcus sciuri Streptococcus salivarius subs icus p. salivarius Streptococcus epide Streptococcus sinensis Streptococcus salivarius subs rmidis p. thermophilus Streptococcus equi Streptococcus sobrinus Streptococcus oligofermentan s Streptococcus faeca Streptococcus suis Streptococcus oralis lis Streptococcus faeci Streptococcus thalasse Peptostreptococcus prevotii um miae Streptococcus ferus Streptococcus thermoph Peptostreptococcus russellii ilus Streptococcus galli Streptococcus thoralten narum sis Streptococcus gallo Streptococcus uberis lyticus Streptococcus halot Streptococcus urinalis olerans Streptococcus hans Streptococcus ursoris enii Streptococcus hillye Streptococcus vaginalis ri Streptococcus himal Streptococcus varani ayensis Streptococcus homi Streptococcus vestibula nis ris Streptococcus huma Streptococcus vicugnae nilactis Streptococcus hyoin Streptococcus vulneris testinalis Streptococcus hyov Streptococcus waius aginalis Streptococcus ilei Streptococcus xiaochunl ingii Streptococcus infan Streptococcus zalophi tis Streptococcus inter Peptostreptococcus ana medius erobius Streptococcus intest Peptostreptococcus asa inalis ccharolyticus Streptococcus lactis Peptostreptococcus faec alis Streptococcus meri Peptostreptococcus har onis ei Streptococcus micr Peptostreptococcus heli oaerophilica otrinreducens Streptococcus mitis Peptostreptococcus mag nus Streptococcus morb Peptostreptococcus octa illorum vius Streptococcus moro Peptostreptococcus par ccensis vulus Streptococcus muta Peptostreptococcus por ns ci The composition of the present invention may further comprise one or more bacterial strains from the genus selected from Lactobacillus, Leuconostoc, Lactococcus, Enterococcus, Weissella, Pediococcus, Aerococcus, Sporolactobacillus and Bifidobacterium wherein the bacterial strains are selected from Table 3 as mentioned herein below; Table 3 Lactobacillus species Lactobacillus Lactobacillus LacticaseiBacillu Lactobacillus acetotolerans jensenii s casei. gasseri Lactobacillus Lactobacillus Ligilactobacillus Lactobacillus acidophilus johnsonii salivarius. helveticus Lactobacillus Lactobacillus Limosilactobacill Lactobacillus amylolyticus kefiranofaciens us fermentum hominis Lactobacillus Lactobacillus LacticaseiBacillu Lactobacillus iners amylovorus kimbladii s rhamnosus (previously Lactobacillus rhamnosus) Lactobacillus Lactobacillus Limosilactobacill Lactobacillus apis kitasatonis us reuteri intestinalis Lactobacillus Lactobacillus Lactobacillus Lactobacillus bombicola mulieris rodentium equicursoris Lactobacillus Lactobacillus Lactobacillus Lactobacillus colini paragasseri rogosae fornicalis Lactobacillus Lactobacillus Lactobacillus Lactobacillus crispatus pasteurii taiwanensis gallinarum Lactobacillus Lactobacillus delbrueckii thermophilus Leuconostoc species Leuconostoc Leuconostoc Leuconostoc Leuconostoc carnosum gasicomitatum lactis pseudomesenteroid es Leuconostoc Leuconostoc Leuconostoc Leuconostoc rapi citreum gelidum litchi Leuconostoc Leuconostoc Leuconostoc Leuconostoc falkenbergense holzapfelii mesenteroides suionicum Leuconostoc Leuconostoc Leuconostoc fallax inhae miyukkimchii Leuconostoc Leuconostoc Leuconostoc garlicum kimchii palmae Lactococcus species Lactococcus Lactococcus Lactococcus Lactococcus allomyrinae garvieae laudensis protaetiae Lactococcus Lactococcus Lactococcus Lactococcus carnosus hircilactis nasutitermitis raffinolactis Lactococcus Lactococcus Lactococcus Lactococcus chungangensis hodotermopsidis paracarnosus reticulitermitis Lactococcus Lactococcus Lactococcus Lactococcus cremoris insecticola petaurid taiwanensis Lactococcus Lactococcus Lactococcus Lactococcus formosensis kimchii piscium termiticola Lactococcus Lactococcus Lactococcus fujiensis lactis plantarum Enterococcus species Enterococcus Enterococcus Enterococcus Enterococcus aquimarinus cecorum haemoperoxidus mundtii Enterococcus Enterococcus Enterococcus Enterococcus asini columbae hermanniensis olivae Enterococcus Enterococcus Enterococcus Enterococcus avium crotali hirae pallens Enterococcus Enterococcus Enterococcus Enterococcus bulliens devriesei hulanensis phoeniculicola Enterococcus Enterococcus Enterococcus Enterococcus burkinafasonensi diestrammenae innesii plantarum s Enterococcus Enterococcus Enterococcus Enterococcus caccae dispar italicus pseudoavium Enterococcus Enterococcus Enterococcus Enterococcus camelliae durans lactis quebecensis Enterococcus Enterococcus Enterococcus Enterococcus canintestini eurekensis lemanii raffinosus Enterococcus Enterococcus Enterococcus Enterococcus ratti canis faecalis malodoratus Enterococcus Enterococcus Enterococcus Enterococcus casseliflavus faecium massiliensis rivorum Enterococcus Enterococcus Enterococcus Enterococcus rotai sulfureus gallinarum mediterraneensis Enterococcus Enterococcus Enterococcus Enterococcus solitarius gilvus moraviensis saccharolyticus Enterococcus Enterococcus saigonensis silesiacus Weissella species Weissella Weissella Weissella Weissella beninensis cryptocerci hellenica paramesenteroides Weissella bombi Weissella Weissella Weissella diestrammenae kandleri sagaensis Weissella ceti Weissella fabalis Weissella Weissella soli koreensis Weissella cibaria Weissella fabaria Weissella minor Weissella thailandensis Weissella Weissella Weissella Weissella uvarum coleopterorum ghanensis muntiaci Weissella Weissella oryzae Weissella halotolerans viridescens Pediococcus species Pediococcus Pediococcus Pediococcus Pediococcus acidilactici claussenii inopinatus perniciosus Pediococcus Pediococcus Pediococcus Pediococcus argentinicus damnosus parvulus siamensis Pediococcus Pediococcus Pediococcus Pediococcus stilesii cellicola ethanolidurans pentosaceus Aerococcus species Aerococcus Aerococcus suis Aerococcus Aerococcus christensenii urinaehominis urinaeequi Aerococcus Aerococcus Aerococcus sanguinicola urinae viridans Sporolactobacillus species Sporolactobacill Sporolactobacill Sporolactobacillu Sporolactobacillus us dextrus us kofuensis s laevolacticus nakayamae Sporolactobacill Sporolactobacill Sporolactobacillu Sporolactobacillus us inulinus us laevis s vineae terrae Bifidobacterium species Bifidobacterium Bifidobacterium Bifidobacterium Bifidobacterium actinocoloniifor bifidum dentium lemurum me Bifidobacterium Bifidobacterium Bifidobacterium Bifidobacterium adolescentis bombi erythrocebi leontopitheci Bifidobacterium Bifidobacterium Bifidobacterium Bifidobacterium aemilianum boum faecale longum Bifidobacterium Bifidobacterium Bifidobacterium Bifidobacterium aerophilum breve felsineum magnum Bifidobacterium Bifidobacterium Bifidobacterium Bifidobacterium amazonense callimiconis gallicum margollesii Bifidobacterium Bifidobacterium Bifidobacterium Bifidobacterium angulatum callitrichidarum gallinarum merycicum Bifidobacterium Bifidobacterium Bifidobacterium Bifidobacterium animalis callitrichos globosum miconis Bifidobacterium Bifidobacterium Bifidobacterium Bifidobacterium anseris canis goeldii miconisargentati Bifidobacterium Bifidobacterium Bifidobacterium Bifidobacterium apousia castoris hapali minimum Bifidobacterium Bifidobacterium Bifidobacterium Bifidobacterium apri catenulatum indicum mongoliense Bifidobacterium Bifidobacterium Bifidobacterium Bifidobacterium aquikefiri catulorum italicum moraviense Bifidobacterium Bifidobacterium Bifidobacterium Bifidobacterium asteroides cebidarum jacchi moukalabense Bifidobacterium Bifidobacterium Bifidobacterium Bifidobacterium avesanii choerinum pseudocatenulatu myosotis m Bifidobacterium Bifidobacterium Bifidobacterium Bifidobacterium biavatii choladohabitans pseudolongum oedipodis Bifidobacterium Bifidobacterium Bifidobacterium Bifidobacterium ruminantium choloepi psychraerophilum olomucense Bifidobacterium Bifidobacterium. Bifidobacterium Bifidobacterium saguini. colobi pullorum panos Bifidobacterium Bifidobacterium Bifidobacterium Bifidobacterium. saguinibicoloris criceti ramosum parmae Bifidobacterium Bifidobacterium Bifidobacterium Bifidobacterium samirii cuniculi reuteri pluvialisilvae Bifidobacterium Bifidobacterium Bifidobacterium Bifidobacterium santillanense stellenboschense rousetti polysaccharolyticu m Bifidobacterium Bifidobacterium Bifidobacterium Bifidobacterium scaligerum subtile vansinderenii pongonis Bifidobacterium Bifidobacterium Bifidobacterium Bifidobacterium scardovii thermacidophilu xylocopae. porcinum m Bifidobacterium Bifidobacterium Bifidobacterium Bifidobacterium simiarum tibiigranuli vespertilionis primatium Bifidobacterium simiiventris In a preferred embodiment the present invention discloses pharmaceutical composition or combination, comprising purified bacterial mixture of Bacillus subtilis and Streptococcus thermophilus wherein Bacillus subtilis has an MTCC assigned number MTCC 25874 (ZMT129) and Streptococcus thermophilus has an MTCC assigned number MTCC 25871 (ZMT121). In a further preferred embodiment the present invention discloses pharmaceutical composition or combination, comprising purified bacterial mixture of Bacillus subtilis and Streptococcus thermophilus wherein Bacillus subtilis has an MTCC assigned number MTCC 25872 (ZMT122) and Streptococcus thermophilus has an MTCC assigned number MTCC 25871 (ZMT121). In yet another preferred embodiment the present invention discloses pharmaceutical composition or combination, comprising purified bacterial mixture of Bacillus subtilis and Streptococcus thermophilus wherein Bacillus subtilis has an MTCC assigned number MTCC 25873 (ZMT128) and Streptococcus thermophilus has an MTCC assigned number MTCC 25871 (ZMT121). In another preferred embodiment the present invention discloses pharmaceutical composition or combination, comprising purified bacterial mixture of Bacillus velezensis and Streptococcus thermophilus wherein Bacillus velezensis has an MTCC assigned number MTCC 25860 (ZMT148) and Streptococcus thermophilus has an MTCC assigned number MTCC 25871 (ZMT121). In another preferred embodiment the present invention discloses pharmaceutical composition or combination, comprising purified bacterial mixture of Bacillus velezensis and Streptococcus infantarius wherein Bacillus velezensis has an MTCC assigned number MTCC 25860 (ZMT148) and Streptococcus infantarius has an MTCC assigned number MTCC 25870 (ZMT114). In a still another preferred embodiment the present invention discloses pharmaceutical composition or combination, comprising purified bacterial mixture of Bacillus subtilis and Streptococcus infantarius wherein Bacillus subtilis has an MTCC assigned number MTCC 25872 (ZMT122) and Streptococcus infantarius has an MTCC assigned number MTCC 25870 (ZMT114). In another preferred embodiment the present invention discloses pharmaceutical composition or combination, comprising purified bacterial mixture of Bacillus subtilis and Streptococcus infantarius wherein Bacillus subtilis has an MTCC assigned number MTCC 25873 (ZMT128) and Streptococcus infantarius has an MTCC assigned number MTCC 25870 (ZMT114). In yet another preferred embodiment the present invention discloses pharmaceutical composition or combination, comprising purified bacterial mixture of Bacillus subtilis and Streptococcus infantarius wherein Bacillus subtilis has an MTCC assigned number MTCC 25874 (ZMT129) and Streptococcus infantarius has an MTCC assigned number MTCC 25870 (ZMT114). The present invention provides pharmaceutical compositions of bacterial strains comprising genus Bacillus and genus Streptococcus as disclosed in the specification. The present invention further relates to preparation of compositions as embodied herein. In some embodiments the present invention provides a process of making pharmaceutical composition. The process includes isolation of bacteria from imported NOD Scid gamma mice (NSG mice). The NSG mice were imported from Jackson Laboratory, ME, USA. The imported mice were treated with Dextran Sulfate Salt (DSS) to create the inflammatory bowel disease model in the said mice. The detailed process has been further exemplified in the examples below. The bacterial mixtures were isolated from the colon of these diseased mice and colonized in various bacteriological agar media. The agar media includes but not limited to, nutrient agar (NA), tryptic soy agar (TSA), HiBacillus agar (HBA), de man-rogosa-sharpe agar (MRSA). The morphologically different isolated colonies observed on plates were marked and picked up using a sterile loop or an isolator. The cultures were streaked on general bacteriological media as mentioned above to obtain pure culture. The isolated bacteria were cryopreserved at -80 °C. The isolated bacteria were characterized for determination of 16S ribosomal RNA. The below table describes 16S ribosomal RNA sequences of the various isolated bacterial strains. ZMT culture ID 16S ribosomal RNA (MTCC No) ZMT141 TGGCGGCAGGCCTAACACATGCAAGTCGAACGGTAACAGGAAGCAGCTTG (MTCC CTGCTTCGCTGACGAGTGGCGGACGGGTGAGTAATGTCTGGGAAACTGCCT 25861) GATGGAGGGGGATAACTACTGGAAACGGTAGCTAATACCGCATAACGTCG CAAGACCAAAGAGGGGGACCTTCGGGCCTCTTGCCATCGGATGTGCCCAG ATGGGATTAGCTAGTAGGTGGGGTAACGGCTCACCTAGGCGACGATCCCTA GCTGGTCTGAGAGGATGACCAGCCACACTGGAACTGAGACACGGTCCAGA CTCCTACGGGAGGCAGCAGTGGGGAATATTGCACAATGGGCGCAAGCCTG ATGCAGCCATGCCGCGTGTATGAAGAAGGCCTTCGGGTTGTAAAGTACTTT CAGCGGGGAGGAAGGCGATAAGGTTAATAACCTTGTCGATTGACGTTACCC GCAGAAGAAGCACCGGCTAACTCCGTGCCAGCAGCCGCGGTAATACGGAG GGTGCAAGCGTTAATCGGAATTACTGGGCGTAAAGCGCACGCAGGCGGTC TGTCAAGTCGGATGTGAAATCCCCGGGCTCAACCTGGGAACTGCATTCGAA ACTGGCAGGCTAGAGTCTTGTAGAGGGGGGTAGAATTCCAGGTGTAGCGG TGAAATGCGTAGAGATCTGGAGGAATACCGGTGGCGAAGGCGGCCCCCTG GACAAAGACTGACGCTCAGGTGCGAAAGCGTGGGGAGCAAACAGGATTAG ATACCCTGGTAGTCCACGCCGTAAACGATGTCGACTTGGAGGTTGTGCCCT TGAGGCGTGGCTTCCGGAGCTAACGCGTTAAGTCGACCGCCTGGGGAGTAC GGCCGCAAGGTTAAAACTCAAATGAATTGACGGGGGCCCGCACAAGCGGT GGAGCATGTGGTTTAATTCGATGCAACGCGAAGAACCTTACCTACTCTTGA CATCCAGAGAACTTTCCAGAGATGGATTGGTGCCTTCGGGAACTCTGAGAC AGGTGCTGCATGGCTGTCGTCAGCTCGTGTTGTGAAATGTTGGGTTAAGTC CCGCAACGAGCGCAACCCTTATCCTTTGTTGCCAGCGGTCCGGCCGGGAAC TCAAAGGAGACTGCCAGTGATAAACTGGAGGAAGGTGGGGATGACGTCAA GTCATCATGGCCCTTACGAGTAGGGCTACACACGTGCTACAATGGCGCATA CAAAGAGAAGCGACCTCGCGAGAGCAAGCGGACCTCATAAAGTGCGTCGT AGTCCGGATTGGAGTCTGCAACTCGACTCCATGAAGTCGGAATCGCTAGTA ATCGTGGATCAGAATGCCACGGTGAATACGTTCCCGGGCCTTGTACACACC GCCCGTCACACCATGGGAGTGGGTTGCAAAAGAAGTAGGTAGCTTAACCTT CGGGAGGGCGCTTACCACTTTGTGATT ZMT culture ID 16S ribosomal RNA (MTCC No) ZMT128 CGTGCCTAATACATGCAAGTCGAGCGGACAGATGGGAGCTTGCTCCCTGAT (MTCC GTTAGCGGCGGACGGGTGAGTAACACGTGGGTAACCTGCCTGTAAGACTG 25873) GGATAACTCCGGGAAACCGGGGCTAATACCGGATGGTTGTTTGAACCGCAT GGTTCAAACATAAAAGGTGGCTTCGGCTACCACTTACAGATGGACCCGCGG CGCATTAGCTAGTTGGTGAGGTAACGGCTCACCAAGGCAACGATGCGTAGC CGACCTGAGAGGGTGATCGGCCACACTGGGACTGAGACACGGCCCAGACT CCTACGGGAGGCAGCAGTAGGGAATCTTCCGCAATGGACGAAAGTCTGAC GGAGCAACGCCGCGTGAGTGATGAAGGTTTTCGGATCGTAAAGCTCTGTTG TTAGGGAAGAACAAGTACCGTTCGAATAGGGCGGTACCTTGACGGTACCTA ACCAGAAAGCCACGGCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGG TGGCAAGCGTTGTCCGGAATTATTGGGCGTAAAGGGCTCGCAGGCGGTTTC TTAAGTCTGATGTGAAAGCCCCCGGCTCAACCGGGGAGGGTCATTGGAAAC TGGGGAACTTGAGTGCAGAAGAGGAGAGTGGAATTCCACGTGTAGCGGTG AAATGCGTAGAGATGTGGAGGAACACCAGTGGCGAAGGCGACTCTCTGGT CTGTAACTGACGCTGAGGAGCGAAAGCGTGGGGAGCGAACAGGATTAGAT ACCCTGGTAGTCCACGCCGTAAACGATGAGTGCTAAGTGTTAGGGGGTTTC CGCCCCTTAGTGCTGCAGCTAACGCATTAAGCACTCCGCCTGGGGAGTACG GTCGCAAGACTGAAACTCAAAGGAATTGACGGGGGCCCGCACAAGCGGTG GAGCATGTGGTTTAATTCGAAGCAACGCGAAGAACCTTACCAGGTCTTGAC ATCCTCTGACAATCCTAGAGATAGGACGTCCCCTTCGGGGGCAGAGTGACA GGTGGTGCATGGTTGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCC CGCAACGAGCGCAACCCTTGATCTTAGTTGCCAGCATTCAGTTGGGCACTC TAAGGTGACTGCCGGTGACAAACCGGAGGAAGGTGGGGATGACGTCAAAT CATCATGCCCCTTATGACCTGGGCTACACACGTGCTACAATGGACAGAACA AAGGGCAGCGAAACCGCGAGGTTAAGCCAATCCCACAAATCTGTTCTCAGT TCGGATCGCAGTCTGCAACTCGACTGCGTGAAGCTGGAATCGCTAGTAATC GCGGATCAGCATGCCGCGGTGAATACGTTCCCGGGCCTTGTACACACCGCC CGTCACACCACGAGAGTTTGTAACACCCGAAGTCGGTGAGGTAACCTTTTA GG ZMT148 ATGGGAGCTTGCTCCCTGATGTTAGCGGCGGACGGGTGAGTAACACGTGGG (MTCC TAACCTGCCTGTAAGACTGGGATAACTCCGGGAAACCGGGGCTAATACCG 25860) GATGGTTGTYTGAACCGCATGGTTCAGACATAAAAGGTGGCTTCGGCTACC ACTTACAGATGGACCCGCGGCGCATTAGCTAGTTGGTGAGGTAACGGCTCA CCAAGGCGACGATGCGTAGCCGACCTGAGAGGGTGATCGGCCACACTGGG ACTGAGACACGGCCCAGACTCCTACGGGAGGCAGCAGTAGGGAATCTTCC GCAATGGACGAAAGTCTGACGGAGCAACGCCGCGTGAGTGATGAAGGTTT TCGGATCGTAAAGCTCTGTTGTTAGGGAAGAACAAGTGCCGTTCAAATAGG GCGGCACCTTGACGGTACCTAACCAGAAAGCCACGGCTAACTACGTGCCA GCAGCCGCGGTAATACGTAGGTGGCAAGCGTTGTCCGGAATTATTGGGCGT AAAGGGCTCGCAGGCGGTTTCTTAAGTCTGATGTGAAAGCCCCCGGCTCAA CCGGGGAGGGTCATTGGAAACTGGGGAACTTGAGTGCAGAAGAGGAGAGT GGAATTCCACGTGTAGCGGTGAAATGCGTAGAGATGTGGAGGAACACCAG TGGCGAAGGCGACTCTCTGGTCTGTAACTGACGCTGAGGAGCGAAAGCGT GGGGAGCGAACAGGATTAGATACCCTGGTAGTCCACGCCGTAAACGATGA GTGCTAAGTGTTAGGGGGTTTCCGCCCCTTAGTGCTGCAGCTAACGCATTA AGCACTCCGCCTGGGGAGTACGGTCGCAAGACTGAAACTCAAAGGAATTG ACGGGGGCCCGCACAAGCGGTGGAGCATGTGGTTTAATTCGAAGCAACGC GAAGAACCTTACCAGGTCTTGACATCCTCTGACAATCCTAGAGATAGGACG TCCCCTTCGGGGGCAGAGTGACAGGTGGTGCATGGTTGTCGTCAGCTCGTG TCGTGAGATGTTGGGTTAAGTCCCGCAACGAGCGCAACCCTTGATCTTAGT TGCCAGCATTCAGTTGGGCACTCTAAGGTGACTGCCGGTGACAAACCGGAG GAAGGTGGGGATGACGTCAAATCATCATGCCCCTTATGACCTGGGCTACAC ACGTGCTACAATGGACAGAACAAAGGGCAGCGAAACCGCGAGGTTAAGCC AATCCCACAAATCTGTTCTCAGTTCGGATCGCAGTCTGCAACTCGACTGCG TGAAGCTGGAATCGCTAGTAATCGCGGATCAGCATGCCGCGGTGAATACGT TCCCGGGCCTTGTACACACCGCCCGTCACACCACGAGAGTTTGTAACACCC GAAGTCGGTGAGGTAACCTTTATGGAGCCAGCCGCCGAAGGTGGGACAGA TGATTGGGGGTGAAGTCGTAACAG ZMT129 TTATCGGAGAGTTTGATCCTGGCTCAGGACGAACGCTGGCGGCGTGCCTAA (MTCC TACATGCAAGTCGAGCGGACAGATGGGAGCTTGCTCCCTGATGTTAGCGGC 25874) GGACGGGTGAGTAACACGTGGGTAACCTGCCTGTAAGACTGGGATAACTC CGGGAAACCGGGGCTAATACCGGATGGTTGTTTGAACCGCATGGTTCAAAC ATAAAAGGTGGCTTCGGCTACCACTTACAGATGGACCCGCGGCGCATTAGC TAGTTGGTGAGGTAACGGCTCACCAAGGCGACGATGCGTAGCCGACCTGA GAGGGTGATCGGCCACACTGGGACTGAGACACGGCCCAGACTCCTACGGG AGGCAGCAGTAGGGAATCTTCCGCAATGGACGAAAGTCTGACGGAGCAAC GCCGCGTGAGTGATGAAGGTTTTCGGATCGTAAAGCTCTGTTGTTAGGGAA GAACAAGTACCGTTCGAATAGGGCGGTACCTTGACGGTACCTAACCAGAA AGCCACGGCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGGTGGCAAG CGTTGTCCGGAATTATTGGGCGTAAAGGGCTCGCAGGCGGTTTCTTAAGTC TGATGTGAAAGCCCCCGGCTCAACCGGGGAGGGTCATTGGAAACTGGGGA ACTTGAGTGCAGAAGAGGAGAGTGGAATTCCACGTGTAGCGGTGAAATGC GTAGAGATGTGGAGGAACACCAGTGGCGAAGGCGACTCTCTGGTCTGTAA CTGACGCTGAGGAGCGAAAGCGTGGGGAGCGAACAGGATTAGATACCCTG GTAGTCCACGCCGTAAACGATGAGTGCTAAGTGTTAGGGGGTTTCCGCCCC TTAGTGCTGCAGCTAACGCATTAAGCACTCCGCCTGGGGAGTACGGTCGCA AGACTGAAACTCAAAGGAATTGACGGGGGCCCGCACAAGCGGTGGAGCAT GTGGTTTAATTCGAAGCAACGCGAAGAACCTTACCAGGTCTTGACATCCTC TGACAATCCTAGAGATAGGACGTCCCCTTCGGGGGCAGAGTGACAGGTGG TGCATGGTTGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCGCAA CGAGCGCAACCCTTGATCTTAGTTGCCAGCATTCAGTTGGGCACTCTAAGG TGACTGCCGGTGACAAACCGGAGGAAGGTGGGGATGACGTCAAATCATCA TGCCCCTTATGACCTGGGCTACACACGTGCTACAATGGACAGAACAAAGGG CAGCGAAACCGCGAGGTTAAGCCAATCCCACAAATCTGTTCTCAGTTCGGA TCGCAGTCTGCAACTCGACTGCGTGAAGCTGGAATCGCTAGTAATCGCGGA TCAGCATGCCGCGGTGAATACGTTCCCGGGCCTTGTACACACCGCCCGTCA CACCACGAGAGTTTGTAACACCCGAAGTCGGTGAGGTAACCTTTTAGGAGC CAGCCGCCGAAGGTGGGACAGATGATTGGGGTGAAGTCGTAACAAGGTAG CCGTATCGGAAGGTGCGGCTGGATCACCTCCTTT ZMT114 TTAAATGAGAGTTTGATCCTGGCTCAGGACGAACGCTGGCGGCGTGCCTAA (MTCC TACATGCAAGTAGAACGCTGAAGACTTTAGCTTGCTAAAGTTGGAAGAGTT 25870) GCGAACGGGTGAGTAACGCGTAGGTAACCTGCCTACTAGCGGGGGATAAC TATTGGAAACGATAGCTAATACCGCATAACAGCATTTAACCCATGTTAGAT GCTTGAAAGGAGCAATTGCTTCACTAGTAGATGGACCTGCGTTGTATTAGC TAGTTGGTGAGGTAACGGCTCACCAAGGCGACGATACATAGCCGACCTGA GAGGGTGATCGGCCACACTGGGACTGAGACACGGCCCAGACTCCTACGGG AGGCAGCAGTAGGGAATCTTCGGCAATGGGGGCAACCCTGACCGAGCAAC GCCGCGTGAGTGAAGAAGGTTTTCGGATCGTAAAGCTCTGTTGTAAGAGAA GAACGTGTGTGAGAGTGGAAAGTTCACACAGTGACGGTAACTTACCAGAA AGGGACGGCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGGTCCCGAG CGTTGTCCGGATTTATTGGGCGTAAAGCGAGCGCAGGCGGTTTAATAAGTC TGAAGTTAAAGGCAGTGGCTTAACCATTGTTCGCTTTGGAAACTGTTAGAC TTGAGTGCAGAAGGGGAGAGTGGAATTCCATGTGTAGCGGTGAAATGCGT AGATATATGGAGGAACACCGGTGGCGAAAGCGGCTCTCTGGTCTGTAACTG ACGCTGAGGCTCGAAAGCGTGGGGAGCAAACAGGATTAGATACCCTGGTA GTCCACGCCGTAAACGATGAGTGCTAGGTGTTAGGCCCTTTCCGGGGCTTA GTGCCGCAGCTAACGCATTAAGCACTCCGCCTGGGGAGTACGACCGCAAG GTTGAAACTCAAAGGAATTGACGGGGGCCCGCACAAGCGGTGGAGCATGT GGTTTAATTCGAAGCAACGCGAAGAACCTTACCAGGTCTTGACATCCCGAT GCTATTCCTAGAGATAGGAAGTTTCTTCGGAACATCGGTGACAGGTGGTGC ATGGTTGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCGCAACGA GCGCAACCCCTATTGTTAGTTGCCATCATTAAGTTGGGCACTCTAGCGAGA CTGCCGGTAATAAACCGGAGGAAGGTGGGGATGACGTCAAATCATCATGC CCCTTATGACCTGGGCTACACACGTGCTACAATGGTTGGTACAACGAGTCG CGAGTCGGTGACGGCAAGCAAATCTCTTAAAGCCAATCTCAGTTCGGATTG TAGGCTGCAACTCGCCTACATGAAGTCGGAATCGCTAGTAATCGCGGATCA GCACGCCGCGGTGAATACGTTCCCGGGCCTTGTACACACCGCCCGTCACAC CACGAGAGTTTGTAACACCCGAAGTCGGTGAGGTAACCTTTTAGGAGCCAG CCGCCTAAGGTGGGATAGATGATTGGGGTGAAGTCGTAACAAGGTAGCCG TATCGGAAGGTGCGGCTGGATCACCTCCTTT ZMT culture ID 16S ribosomal RNA (MTCC No.) ZMT121 ATTGTTGGGATCCTTTCCGGGGCATTCAGTGCTCGCAGCTAACGCATTAAG (MTCC CACTCCGCCTGGGGAGTACGACCGCAAGGTTGAAACTCAAAGGAATTGAC 25871) GGGGGCCCGCACAAGCGGTGGAGCATGTGGTTTAATTCGAAGCAACGCGA AGAACCTTACCAGGTCTTGACATCCCGATGCTATTTCTAAAGATAGAAAGT TACTTCGGTACATCGGTGACAGGTGGTGCATGGTTGTCGTCAGCTCGTGTC GTGAGATGTTGGGTTAAGTCCCGCAACGAGCGCAACCCCTATTGTTAGTTG CCATCATTCAGTTGGGCACTCTAGCGAGACTGCCGGTAATAAACCGGAGGA AGGTGGGGATGACGTCAAATCATCATGCCCCTTATGACCTGGGCTACACAC GTGCTACAATGGTTGGTACAACGAGTTGCGAGTCGGTGACGGCGAGCTAAT CTCTTAAAGCCAATCTCAGTTCGGATTGTAGGCTGCAACTCGCCTACATGA AGTCGGAATCGCTAGTAATCGCGGATCAGCACGCCGCGGTGAATACGTTCC CGGGCCTTGTACACACCGCCCGTCACACCACGAGAGTTTGTAACACCCGAA GTCGGTGAGGTAACCTTTTGGAGCCAGCCGCCTAAGGTGGGACAGATGATT GGGGTGAAGTCGTACAAGGGGTAACCGAGAGGGGGCCCCCCGGGTTTGTA AGGCCTCAGAGGGCGTTAACAGGCGGGAGGGCCGCTATGGATAAGAGGTG TTCCTCCATATATCTCCGCATTTCACCGCTCCAGGTGGAAATCCACTCCCGC CTTCCGCACGCCGTTTTGGAGTTTTCAAGAGCGATATCTGGGGTGAGCCCC CCGCCTTTGATAAAAAAATATAAGAAACGGGCGGGCGCCCGTTTACCCGCA GAAAAATTCGGGAAAAAGTGGGGGGACACCAATATATAACCGGG ZMT culture ID 16S ribosomal RNA (MTCC No.) ZMT122 TTAGGGGGGTTTCCGCCCCTTAGTGCTGCAGCTAACGCATTAAGCACTCCG (MTCC CCTGGGGAGTACGGTCGCAAGACTGAAACTCAAAGGAATTGACGGGGGCC 25872) CGCACAAGCGGTGGAGCATGTGGTTTAATTCGAAGCAACGCGAAGAACCT TACCAGGTCTTGACATCCTCTGACAATCCTAGAGATAGGACGTCCCCTTCG GGGGCAGAGTGACAGGTGGTGCATGGTTGTCGTCAGCTCGTGTCGTGAGAT GTTGGGTTAAGTCCCGCAACGAGCGCAACCCTTGATCTTAGTTGCCAGCAT TCAGTTGGGCACTCTAAGGTGACTGCCGGTGACAAACCGGAGGAAGGTGG GGATGACGTCAAATCATCATGCCCCTTATGACCTGGGCTACACACGTGCTA CAATGGACAGAACAAAGGGCAGCGAAACCGCGAGGTTAAGCCAATCCCAC AAATCTGTTCTCAGTTCGGATCGCAGTCTGCAACTCGACTGCGTGAAGCTG GAATCGCTAGTAATCGCGGATCAGCATGCCGCGGTGAATACGTTCCCGGGC CTTGTACACACCGCCCGTCACACCACGAGAGTTTGTAACACCCGAAGTCGG TGAGGTAACCTTTTAGGAGCCAGCCGCCGAAGGTGGGACAGATGATTGGG GTGAAGTCGTACAAGGGGTAACCGGAACGGAACCCTCCGGACCCGTAACT GACCCTTAAGGAACGTAACCGGGGGGGAGCGTACCCGGATTACAAAGGGG TTCCTCCCATCCCTAAACAATTTAACCGCTAACGTTGAAGGGCACTCCCCCC TTCGGCGCTCAGGTTCCCCATTTCCAATGACCCCCCCGGGATGAACCCGGG GGGTTTTCACTCCAAATTAAAAAACCGGCGGGCAACCCTTTTAGCCCAAAA AGTTCCGGAAAACCGAGGGCCCCCAAATAATACCCGGGGGGGGCTGG ZMT 16S ribosomal RNA culture IDZMT147GGGCGGCAGGCCTAACACATGCAAGTCGAACGGTAACAGGAAGCAGCTTG CTGCTTCGCTGACGAGTGGCGGACGGGTGAGTAATGTCTGGGAAACTGCCT GATGGAGGGGGATAACTACTGGAAACGGTAGCTAATACCGCATAATGTCG CAAGACCAAAGAGGGGGACCTTCGGGCCTCTTGCCATCGGATGTGCCCAG ATGGGATTAGCTAGTAGGTGGGGTAACGGCTCACCTAGGCGACGATCCCTA GCTGGTCTGAGAGGATGACCAGCCACACTGGAACTGAGACACGGTCCAGA CTCCTACGGGAGGCAGCAGTGGGGAATATTGCACAATGGGCGCAAGCCTG ATGCAGCCATGCCGCGTGTATGAAGAAGGCCTTCGGGTTGTAAAGTACTTT CAGCGGGGAGGAAGGCGATAAGGTTAATAACCTCGTCGATTGACGTTACC CGCAGAAGAAGCACCGGCTAACTCCGTGCCAGCAGCCGCGGTAATACGGA GGGTGCAAGCGTTAATCGGAATTACTGGGCGTAAAGCGCACGCAGGCGGT CTGTCAAGTCGGATGTGAAATCCCCGGGCTCAACCTGGGAACTGCATTCGA AACTGGCAGGCTAGAGTCTTGTAGAGGGGGGTAGAATTCCAGGTGTAGCG GTGAAATGCGTAGAGATCTGGAGGAATACCGGTGGCGAAGGCGGCCCCCT GGACAAAGACTGACGCTCAGGTGCGAAAGCGTGGGGAGCAAACAGGATTA GATACCCTGGTAGTCCACGCCGTAAACGATGTCGACTTGGAGGTTGTGCCC TTGAGGCGTGGCTTCCGGAGCTAACGCGTTAAGTCGACCGCCTGGGGAGTA CGGCCGCAAGGTTAAAACTCAAATGAATTGACGGGGGCCCGCACAAGCGG TGGAGCATGTGGTTTAATTCGATGCAACGCGAAGAACCTTACCTACTCTTG ACATCCAGAGAACTTTCCAGAGATGGATTGGTGCCTTCGGGAACTCTGAGA CAGGTGCTGCATGGCTGTCGTCAGCTCGTGTTGTGAAATGTTGGGTTAAGT CCCGCAACGAGCGCAACCCTTATCCTTTGTTGCCAGCGGTCCGGCCGGGAA CTCAAAGGAGACTGCCAGTGATAAACTGGAGGAAGGTGGGGATGACGTCA AGTCATCATGGCCCTTACGAGTAGGGCTACACACGTGCTACAATGGCGCAT ACAAAGAGAAGCGACCTCGCGAGAGCAAGCGGACCTCATAAAGTGCGTCG TAGTCCGGATTGGAGTCTGCAACTCGACTCCATGAAGTCGGAATCGCTAGT AATCGTGGATCAGAATGCCACGGTGAATACGTTCCCGGGCCTTGTACACAC CGCCCGTCACACCATGGGAGTGGGTTGCAAAAGAAGTAGGTAGCTTAACCT TCGGGAGGGCGCTTACCACTTT ZMT 16S ribosomal RNA culture IDZMT110GTGCCTAATACATGCAAGTCGAGCGGACAGATGGGAGCTTGCTCCCTGATG TTAGCGGCGGACGGGTGAGTAACACGTGGGTAACCTGCCTGTAAGACTGG GATAACTCCGGGAAACCGGGGCTAATACCGGATGCTTGTTTGAACCGCATG GTTCAAACATAAAAGGTGGCTTCGGCTACCACTTACAGATGGACCCGCGGC GCATTAGCTAGTTGGTGAGGTAATGGCTCACCAAGGCGACGATGCGTAGCC GACCTGAGAGGGTGATCGGCCACACTGGGACTGAGACACGGCCCAGACTC CTACGGGAGGCAGCAGTAGGGAATCTTCCGCAATGGACGAAAGTCTGACG GAGCAACGCCGCGTGAGTGATGAAGGTTTTCGGATCGTAAAGCTCTGTTGT TAGGGAAGAACAAGTACCGTTCGAATAGGGCGGTACCTTGACGGTACCTA ACCAGAAAGCCACGGCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGG TGGCAAGCGTTGTCCGGAATTATTGGGCGTAAAGGGCTCGCAGGCGGTTTC TTAAGTCTGATGTGAAAGCCCCCGGCTCAACCGGGGAGGGTCATTGGAAAC TGGGGAACTTGAGTGCAGAAGAGGAGAGTGGAATTCCACGTGTAGCGGTG AAATGCGTAGAGATGTGGAGGAACACCAGTGGCGAAGGCGACTCTCTGGT CTGTAACTGACGCTGAGGAGCGAAAGCGTGGGGAGCGAACAGGATTAGAT ACCCTGGTAGTCCACGCCGTAAACGATGAGTGCTAAGTGTTAGGGGGTTTC CGCCCCTTAGTGCTGCAGCTAACGCATTAAGCACTCCGCCTGGGGAGTACG GTCGCAAGACTGAAACTCAAAGGAATTGACGGGGGCCCGCACAAGCGGTG GAGCATGTGGTTTAATTCGAAGCAACGCGAAGAACCTTACCAGGTCTTGAC ATCCTCTGACAATCCTAGAGATAGGACGTCCCCTTCGGGGGCAGAGTGACA GGTGGTGCATGGTTGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCC CGCAACGAGCGCAACCCTTGATCTTAGTTGCCAGCATTCAGTTGGGCACTC TAAGGTGACTGCCGGTGACAAACCGGAGGAAGGTGGGGATGACGTCAAAT CATCATGCCCCTTATGACCTGGGCTACACACGTGCTACAATGGACAGAACA AAGGGCAGCGAAACCGCGAGGTTAAGCCAATCCCACAAATCTGTTCTCAGT TCGGATCGCAGTCTGCAACTCGACTGCGTGAAGCTGGAATCGCTAGTAATC GCGGATCAGCATGCCGCGGTGAATACGTTCCCGGGCCTTGTACACACCGCC CGTCACACCACGAGAGTTTGTAACACCCGAAGTCGGTGAGGTAACCTTTTA GGAGCCAGCCGCCGAAGGTGGG ZMT 16S ribosomal RNA culture IDZMT125GCCTAATACATGCAAGTCGAGCGGACAGATGGGAGCTTGCTCCCTGATGTT AGCGGCGGACGGGTGAGTAACACGTGGGTAACCTGCCTGTAAGACTGGGA TAACTCCGGGAAACCGGGGCTAATACCGGATGGTTGTTTGAACCGCATGGT TCAGACATAAAAGGTGGCTTCGGCTACCACTTACAGATGGACCCGCGGCGC ATTAGCTAGTTGGTGAGGTAACGGCTCACCAAGGCGACGATGCGTAGCCG ACCTGAGAGGGTGATCGGCCACACTGGGACTGAGACACGGCCCAGACTCC TACGGGAGGCAGCAGTAGGGAATCTTCCGCAATGGACGAAAGTCTGACGG AGCAACGCCGCGTGAGTGATGAAGGTTTTCGGATCGTAAAGCTCTGTTGTT AGGGAAGAACAAGTGCCGTTCAAATAGGGCGGCACCTTGACGGTACCTAA CCAGAAAGCCACGGCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGGT GGCAAGCGTTGTCCGGAATTATTGGGCGTAAAGGGCTCGCAGGCGGTTTCT TAAGTCTGATGTGAAAGCCCCCGGCTCAACCGGGGAGGGTCATTGGAAACT GGGGAACTTGAGTGCAGAAGAGGAGAGTGGAATTCCACGTGTAGCGGTGA AATGCGTAGAGATGTGGAGGAACACCAGTGGCGAAGGCGACTCTCTGGTC TGTAACTGACGCTGAGGAGCGAAAGCGTGGGGAGCGAACAGGATTAGATA CCCTGGTAGTCCACGCCGTAAACGATGAGTGCTAAGTGTTAGGGGGTTTCC GCCCCTTAGTGCTGCAGCTAACGCATTAAGCACTCCGCCTGGGGAGTACGG TCGCAAGACTGAAACTCAAAGGAATTGACGGGGGCCCGCACAAGCGGTGG AGCATGTGGTTTAATTCGAAGCAACGCGAAGAACCTTACCAGGTCTTGACA TCCTCTGACAATCCTAGAGATAGGACGTCCCCTTCGGGGGCAGAGTGACAG GTGGTGCATGGTTGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCC GCAACGAGCGCAACCCTTGATCTTAGTTGCCAGCATTCAGTTGGGCACTCT AAGGTGACTGCCGGTGACAAACCGGAGGAAGGTGGGGATGACGTCAAATC ATCATGCCCCTTATGACCTGGGCTACACACGTGCTACAATGGACAGAACAA AGGGCAGCGAAACCGCGAGGTTAAGCCAATCCCACAAATCTGTTCTCAGTT CGGATCGCAGTCTGCAACTCGACTGCGTGAAGCTGGAATCGCTAGTAATCG CGGATCAGCATGCCGCGGTGAATACGTTCCCGGGCCTTGTACACACCGCCC GTCACACCACGAGAGTTTGTAACACCCGAAGTCGGTGAGGTAACCTTTAAG GAGCCAGCCGCCGAAGGTGGGACAGATGAT In some embodiment, the present invention provides the process of preparing pharmaceutical composition that comprises isolation of bacteria from suitable mice, characterization of isolated bacteria, cryopreserving the isolated bacteria, preparing composition of isolated bacteria with suitable pharmaceutical excipients. The pharmaceutical excipients and additional substances present in, the pharmaceutical composition may include non-cellular materials, for example an extracellular product of non-lactic acid-producing bacteria, a bacterial supplement, suitable binders, fillers, vitamins, minerals, or suitable combinations thereof. Additional ingredients include ingredients to improve handling, suitable preservatives, antioxidants, flavoring agents and the like. For example, in one embodiment, the preparation can include flavoring agents that can flavor the preparation with various flavors such as grape, strawberry, lime, lemon, chocolate, and the like. In one embodiment, the pharmaceutical composition includes microcrystalline cellulose or silicone dioxide as disintegrant. Preservatives can include, for example, benzoic acid, suitable alcohols, for example, ethyl alcohol, and hydroxybenzoates. Antioxidants can include, for example, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), tocopherols (e.g., vitamin E), and ascorbic acid (vitamin C). In some embodiments, the bacteria present in the compositions of the present invention are not in a vegetative (i.e., growth) state prior to being consumed by a human, or prior to delivery to a certain region of the consumer's gastrointestinal tract. Stabilized bacterial populations are generally contained in or combined with a suitable stabilizer, such as an enteric material. In some embodiments, the enteric material is acid-labile, meaning it dissolves when exposed to an acidic environment such as the stomach. Alternatively, the enteric material is acid-stable and base- labile, meaning it will not dissolve in the stomach, but will dissolve in the small intestine. In some embodiments, the enteric material is heat-labile, meaning it is stable at a given temperature, typically above about room temperature but below the human physiological temperature. For example, the enteric material has a melting temperature of at least 30 degrees Celsius. In some embodiments, the pharmaceutical composition of the present invention comprises live cultured bacteria, in vegetative or spore form or as a combination of vegetative and spore forms. Alternatively, the bacteria are provided as purified populations obtained from a microbial material such as a fecal material. In some embodiments, the pharmaceutical composition is administered as a single dose. In some embodiments, the pharmaceutical composition is administered in multiple doses. In some embodiments, a dose of the pharmaceutical composition comprises between 103to 1013colony forming units (CFUs). In some embodiments, a dose of the pharmaceutical composition comprises between 105to 1012colony forming units (CFUs). In some embodiments, a dose of the pharmaceutical composition comprises about 103CFUs. In some embodiments, a dose of the pharmaceutical composition comprises about 104CFUs. In some embodiments, a dose of the pharmaceutical composition comprises about 105CFUs. In some embodiments, a dose of the pharmaceutical composition comprises about 106CFUs. In some embodiments, a dose of the pharmaceutical composition comprises about 107CFUs. In some embodiments, a dose of the pharmaceutical composition comprises about 108CFUs. In some embodiments, a dose of the pharmaceutical composition comprises about 109CFUs. In some embodiments, a dose of the pharmaceutical composition comprises about 1010CFUs. In some embodiments, a dose of the pharmaceutical composition comprises about 1011CFUs. In some embodiments, a dose of the pharmaceutical composition comprises about 1012CFUs. In some embodiments, a dose of the pharmaceutical composition comprises about 1013CFUs. In one embodiment, a composition of the present invention is administered as a pharmaceutical preparation in solid, semi-solid, micro-emulsion, gel, or liquid form. Forms of the compositions that can be used orally include tablets, push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. Tablets can be made by compression or molding, optionally with one or more suitable excipients. In some embodiments, the compositions described herein can be in liquid form. The liquid formulations can comprise, for example, an agent in water-in-solution and / or suspension form or in buffer; and a vehicle comprising polyethoxylated castor oil, alcohol, and / or a polyoxyethylated sorbitan mono-oleate with or without flavoring agents. Each dosage form comprises an effective amount of an active ingredient i.e. bacterial combinations / mixture here and can optionally comprise one or more pharmaceutically inert agents, such as conventional excipients, vehicles e.g. water, buffer, phosphate buffer saline etc., fillers e.g. lactose, calcium carbonate, starch etc., binders e.g. cellulose, methyl cellulose, polyvinyl pyrrolidine etc., disintegrants e.g. sodium starch glycolate, croscarmellose sodium, microcrystalline cellulose etc., pH adjusting substances e.g. sodium hydroxide or hydrochloric acid etc., buffer e.g. phosphate buffer etc., solvents e.g. water, solubilizing agents e.g. ethanol, sorbitol, polyethylene glycols, cyclodextrins, sodium lauryl sulphates etc., sweeteners e.g. sucrose etc., coloring agents, and any other inactive agents that can be included in pharmaceutical dosage forms for oral administration. In some embodiments, the present invention provides the pharmaceutical compositions that are capable of being consumed ad libitum. In instances wherein a dysbiosis is caused by a disease, such disorder is being addressed by administration of the compositions. The total duration of consumption can be from about one week to about 52 weeks, or about four weeks to about twenty six weeks, or about four weeks to about twelve weeks, or about six weeks or about six months. In one embodiment, the total duration of treatment is about 5 days to about 35 days. In one embodiment, the total duration of treatment is about 7 days to about 90 days, or about 7 days to about 60 days, or about 14 days to about 50 days, or about 14 days to about 40 days. In another embodiment, the total duration of treatment is about 30 days. In another embodiment, the total duration of treatment is about 34 days. In another embodiment, the total duration of treatment is about 36 days. In another embodiment, the total duration of treatment is about 38 days. In another embodiment, the total duration of treatment is about 42 days. In another embodiment, the total duration of treatment is about 60 days. In another embodiment, the total duration of treatment is about 90 days. In another embodiment, the total duration of treatment is up to 6 months. In another embodiment, one course of therapy may be followed by another, such as an induction regimen followed by a maintenance regimen. In some embodiments, the present invention provides pharmaceutical compositions that are used in the treatment of autoimmune diseases, inflammatory diseases, intestinal bowel disease (IBD) and allergic diseases. In some embodiments, the present invention provides method of treatment wherein the treatment comprises administration of pharmaceutical composition of the present invention in suitable dosage form and in suitable dosage regimen for the treatment of autoimmune diseases, inflammatory diseases, intestinal bowel disease (IBD) and allergic diseases. In some embodiments the preparations, e.g., compositions are formulated as pharmaceutical preparations for oral, topical, nasal, respiratory, parenteral, intraperitoneal, intravenous, intraarterial, transdermal, sublingual, intramuscular, rectal, trans buccal, vaginal, intraocular, subcutaneous, intraadiposal, iintraarticular, intrathecal administration. In some embodiments, the formulation is a slow release formulation. In some embodiments, the present invention provides pharmaceutical compositions that are used in the prevention of autoimmune diseases, inflammatory diseases, intestinal bowel disease (IBD) and allergic diseases. The pharmaceutical composition of bacterial strains as embodied in the present invention provides significant advancement in treating inflammatory bowel disease (IBD) such as ulcerative colitis as compared to standard of care therapies like Visbiome® or mesalamine. Visbiome® is a composition of Lactobacillus acidophilus DSM24735 / SD5212, Lactobacillus plantarum DSM24730 / SD5209, Lactobacillus paracasei DSM24733 / SD5218, Lactobacillus delbrueckii subsp. bulgaricus DSM24734 / SD5210, Streptococcus thermophilus DSM24731 / SD5207, Bifidobacterium longum DSM24736 / SD5219, Bifidobacterium breve DSM24732 / SD5206 and Bifidobacterium infantis DSM24737 / SD5220. In addition, the composition of the bacterial strains in the present invention provides synergistic effect over individual bacterial strains which is evidenced from the various in-vivo and in-vitro experiments as exemplified herein below. Examples Example 1: Isolation of bacteria from disease animal model. Preparation of disease model NSG mice were procured from The Jackson Laboratory, ME, USA. The imported mice were subsequently housed and quarantined at Animal Research Facility, Zydus Research Centre, Ahmedabad. After their quarantine period, the mice were issued from the animal house for experiments. Thirteen to fourteen week old NSG mice were exposed to Dextran Sulfate Salt (2.5% DSS) in water for 5 days to induce inflammation and gland loss with erosion in the colon. Acute colitis was developed in mice with signs of diarrhea, gross rectal bleeding, and body weight loss after ingesting DSS. Gross changes resulting from DSS administration resemble those occurring in human ulcerative colitis, a subset of inflammatory bowel disease. Mice were assigned to two different groups. Each group consisted of 2-3 animals. One group of animals received DSS while the other group received plain drinking water and served as normal control. On day 6, faeces of the animals were collected from both the DSS naive and DSS treated (consisting of both DSS sensitive and resistant animals) groups. At necropsy, the entire colon and intestine of each mouse were removed and kept on ice before transferring them to the cell biology lab for microbial extraction. Isolation of Bacteria from mice colon Frozen colon samples from NSG mice treated with DSS / untreated as mentioned above were collected from Pharmacology department. Sterile PBS (2-5 mL, pH 7.4) was aseptically added to the colon samples and the samples were homogenized with a hand homogenizer. This was properly mixed and incubated on a shaker incubator at 200 rpm for ~30 min. The resulting homogenized suspension was divided into 2 parts i.e., untreated and treated samples. Isolation: In order to isolate Bacillus (spore formers) and Streptococcus (lactic acid bacteria) from the homogenized suspension, isolation was carried out at aerobic to mild anaerobic conditions. Isolation of spore forming bacilli: For heat treated samples, an aliquot of 2 mL was separated from the homogenized suspension and exposed to 60-80 ˚C for 5-30 minutes. Upon heat shock treatment, the sample tube was transferred to cold water until temperature of the samples become normal (~ 5 minutes). Subsequently, serial dilutions (1:10 to 1: 10,00,000) from these samples were prepared and plated on various bacteriological media such as nutrient agar (NA), tryptic soy agar (TSA), HiCrome Bacillus agar (HBA), brain heart infusion agar, elliker’s agar, soyabean casein digest agar (SCDA), luria bertani (LBA) agar. Lactic acid bacteria isolation An aliquot of 2 mL was separated from the homogenized suspension. Serial dilutions (1:10 to 1: 10,00,000) from these samples were prepared and plated on various bacteriological media such as de Man-Rogosa and Sharpe agar (MRSA), elliker’s agar and Streptococcus selective agar media. The plates were incubated at 30 ˚C to 37 ˚C with and without 5 % CO2for 24-72 hours. Purification / Separation: The morphologically different isolated colonies observed on plates were marked and picked up using sterile loop or isolator. The cultures were streaked on routine bacteriological media like nutrient agar (NA), tryptic soy agar (TSA), HiCrome bacillus agar (HBA) differentiating for Bacillus, elliker’s agar, de Man Rogosa and Sharpe agar (for all the other lactic acid bacteria), soyabean casein digest agar (SCDA), luria bertani (LBA) agar. All the plates were incubated at 30-37˚C for 24-72 hours. Cryopreservation: An isolated colony of pure bacterial isolate was assigned a unique ZMT number. This colony was inoculated aseptically in sterile tryptone soya broth medium (10 mL) and incubated at 37˚C for 16-18 hours at 200 rpm. The other media can also be used such as, nutrient medium, HiCrome bacillus medium, de Man-Rogosa and Sharpe medium, brain heart infusion medium, elliker’s medium, minimal medium, soyabean casein digest medium, luria bertani medium. For lactic acid bacteria, the cultures were grown in sterile de Man Rogosa and Sharpe broth medium. An equal volume of overnight grown bacterial suspension and sterile glycerol were mixed thoroughly so that the final glycerol concentration is 15-20 %. Alternatively, the cultures can be stored on agar plates or slants or stabs in any agar media as mentioned here for short time period. All the cultures were aliquoted aseptically (1 mL) in sterile 1.8 ml cryovials and labelled with the assigned inhouse code (ZMT code). The vials were stored at -80 ˚C. Example 2: In-vitro study of Isolated bacteria pH stability: An isolated colony of bacteria as mentioned in example 1 was inoculated aseptically in sterile tryptone soya broth medium (TSB), nutrient medium, HiBacillus medium, de man-rogosa-sharpe medium, brain heart infusion medium, Hichrome medium, Eliker’s medium, minimal medium, casein-soyabean digest medium, Luria Bertani medium (10-20 mL) and incubated at 30-37 °C for 16-48 hours at 100-500 rpm. The overnight grown cells were harvested by centrifugation at 7000 rpm for 10 min. The cells harvested were resuspended in sterile PBS (pH 7.4) to obtain a dense suspension. An appropriate aliquot of dense suspension was inoculated in sterile TSB at pH 2 and 5 to attain final OD600 ~ 0.5. A sterile TSB media at pH 7.0 inoculated at the same bacterial density served as a control. The suspensions were incubated at 37 °C for 2 hours. Upon incubation, the viability of the treated and control cultures was assessed using standard plate count. Table 4 demonstrate log reduction of viable number of bacterial strains at pH 2 and pH 5 as compared to viable number of bacterial strains in control media i.e. TSB at 5 pH 7.0. Table 4 Log Tolerance at Log Tolerance at pH Sr. no. Strain ID Reduction at Reduction at pH 2 5 pH2.0 / 2Hrs pH5.0 / 2Hrs 1 ZMT110 1 Highly Tolerant <1 Highly Tolerant 2 ZMT112 2 Slightly Tolerant <1 Highly Tolerant 3ZMT114(MTCC 25870)5 Weak <1 Highly Tolerant4 ZMT115 3 Slightly tolerant 1 Highly Tolerant 5 ZMT116 4 Weak 1 Highly Tolerant 6ZMT122(MTCC 25872)4 Weak <1 Highly Tolerant7 ZMT125 3 Slightly tolerant 1 Highly Tolerant 8ZMT128(MTCC 25873)1 Highly Tolerant 1 Highly Tolerant9 ZMT129(MTCC 25874)2 Slightly Tolerant <1 Highly Tolerant10 ZMT141(MTCC 25861)4 Weak <1 Highly Tolerant11 ZMT147 3 Slightly tolerant <1 Highly Tolerant 12 ZMT157 4 Weak <1 Highly Tolerant It was observed from the study that most bacterial strains of the present invention show stability at pH 2.0 as well as pH 5.0. Almost all the strains tested were stable 10 at pH 5.0, however, from all the strains tested, only ZMT112, ZMT 110, ZMT128 and ZMT 129 were found to be relatively stable at pH 2.0. Gastrointestinal juice tolerance assay: A sterile bacteriological medium tryptone soya broth (TSB -20 mL) dispensed in 50 mL sterile tarson tube was inoculated with an isolated colony of test bacteria (test sample). The test sample was incubated 15 at 37°C for 16-18 h at 200 rpm. Next day, the grown cells were harvested by centrifugation at 8000 rpm for 10 min followed by washing of cells with sterile Dulbecco phosphate buffer saline (DPBS - 20 mL). The cells were then resuspended in sterile DPBS to attain OD600 ~ 1.0. Subsequently, an aliquot of 2 mL cell suspension was distributed in three separate sterile 2 mL microfuge tube. The cells were collected by centrifugation at 8000 rpm for 5 min. These cells were resuspended in 2 mL sterile PBS, gastric juice and intestinal juices, and the tubes were labelled as control, experimental (pH 2) and experimental (pH 8), respectively. The tubes were incubated at 37˚C for 3 h (for gastric tolerance) and 4 h and 24 h (for intestinal juice tolerance). Upon incubation, serial dilutions (10-1to 10-7) in sterile PBS were prepared from each tube viz. control, experimental (pH 2) and experimental (pH 8) in a sterile 96-well microtiter plate. For control sample, an aliquot (100 µL) of dilutions viz.10-4to 10-6were spread on TSA plate using sterile spreaders. For experimental samples, an aliquot (100 µL) of each dilution were spread on sterile TSA plate. The plates were incubated at 30-37˚C for 24-48 h. The viable number of cells in control and experimental samples were determined by multiplying the number of colonies in each dilution with dilution factor and subsequently dividing the same with volume of sample plated as follows: ^^. ^^ ^^^^^^^^ × ^^^^^^^^ ^^^^^^^^^ / ^^ =^^^^^^ ^^^^^^The results are as follows in Table 5 and Table 6; Table 5 (Tolerance to simulated gastric juices) Sr. no. Strain ID Log reduction relative to control Inference 1 ZMT128 2 Tolerant (MTCC 25873) 2 ZMT129 3 Tolerant (MTCC 25874) 3 ZMT116 2 Tolerant 4 ZMT122 2 Tolerant (MTCC 25872) 5 ZMT121 >8 Not tolerant (MTCC 25871) 6 ZMT141 >8 Not tolerant (MTCC 25861) 7 ZMT114 >8 Not tolerant (MTCC 25870) Table 6 (Tolerance to simulated intestinal juices) Sr. no. Strain ID Log reduction relative to control Inference 1 ZMT128 1 Tolerant (MTCC 25873) 2 ZMT129 1 Tolerant (MTCC 25874) 3 ZMT116 1 Tolerant 4 ZMT122 1 Tolerant (MTCC 25872) 5 ZMT121 5 Weak Tolerant (MTCC 25871) 6 ZMT141 0 Tolerant (MTCC 25861) 7 ZMT114 3 Weak tolerant (MTCC 25870) It was observed that bacterial strains of the present invention show stability under simulated gastrointestinal juices. This suggests that the strains except few can withstand varying pH, bile, gastric and intestinal enzymes. Antipathogenic activity: An isolated colony of bacteria and test pathogen were inoculated in sterile tryptone soya broth (for Bacillus), de Man-Rogosa and Sharpe medium (for lactic acid bacteria), elliker’s medium (for Streptococcus) minimal medium, casein-soyabean digest medium, Luria Bertani medium (10-20 mL) and incubated at 30-37 ˚C for 16-48 hours at 100-500 rpm. The grown cells were harvested by centrifugation at 2000-7000 rpm for 5-10 min. The cells harvested were resuspended in sterile Phosphate buffer or normal saline or tris buffer or nutrient broth or MRS broth or trypticase soy broth or brain heart infusion broth to obtain a suspension of OD600~ 0.1 to 0.2. For determining anti-pathogenic activity of spore-former Bacillus, the pathogen suspension was spread inoculated on sterile TSA media using a sterile cotton swab and allowed to dry at 25-37 °C. An aliquot of isolated bacteria (OD6000.2) was spot inoculated on agar any medium described above that was pre-inoculated with pathogen. For determining activity of lactic acid bacteria, the pathogen suspension was inoculated aseptically in sterile soft tryptone soya agar medium (0.8 %) and poured on sterile TSA plate. The plates were allowed to solidify. An aliquot of isolated bacteria (OD6000.2) was spot inoculated on agar plate on the medium described above that was pre-inoculated with pathogen. The plates with test pathogens and isolated bacteria alone serve as control. The plates were then incubated 30-37˚C for 24-72 h and observed for zone of inhibition around the isolated bacteria as mentioned in table 7 below. Table 7 S. No. Isolate Antibacterial activity E. coli E. faecalis S. aureus S. typhi 1 ZMT110 + - + + 2 ZMT111 - - - - 3 ZMT112 + - + + 4 ZMT113 + - + + 5 ZMT114 + + + + 6 ZMT115 + + + + 7 ZMT116 + + + + 8 ZMT117 + ++ ++ + 9 ZMT118 - - + - 10 ZMT119 + - + + 11 ZMT120 - + + + 12 ZMT121 - + - - 13 ZMT122 + - + + 14 ZMT123 - - + + 15 ZMT124 - - + - 16 ZMT125 - + + + 17 ZMT126 + - + + 18 ZMT127 - + + + 19 ZMT128 - - + + 20 ZMT129 - + + + 21 ZMT130 - + + + ZMT131 - + + - ZMT132 + - + + ZMT133 - + + - ZMT134 - - - - ZMT135 - - - - ZMT136 - + - - ZMT137 - - + - ZMT138 - - + - ZMT139 - - - - ZMT140 + - + + ZMT141 - - - - ZMT142 ZMT143 + + + - ZMT144 + ++ ++ + ZMT145 + - + + ZMT146 ++ ++ ++ + ZMT147 - - - - ZMT148 ZMT149 - - - - ZMT150 - + + + ZMT151 + - + + ZMT152 - - - - ZMT153 + - + + ZMT154 - + + + ZMT155 - + + + ZMT156 + + + - ZMT157 - - - - ZMT158 - - - - ZMT159 - - - - ZMT160 - - - - (+): 10 mm zone of inhibition observed (++): > 10 mm zone of inhibition observed (-): No zone of inhibition observed IL-8 inhibition assay: Caco2 (ATCC, cat no: HTB-37) cells were seeded in tissue culture treated 96 well plate (10,000 cells / well) in complete minimum essential medium (MEM) with 10 % heat inactivated fetal bovine serum (FBS) and incubated in humidified CO2 incubator at 37 °C for 24 hours. Next day cells were replenished with complete MEM (without antibiotics) and again incubated in CO2incubator at 37 °C for 24 hrs. Next day, Caco2 cells were treated with increasing colony forming unit (CFU) ranging from 0 to 108, of the test bacterial culture. This was followed by stimulation of Caco2 cells with human recombinant IL-1β (1 ng / mL). 6 hours post stimulation, culture supernatant was harvested by centrifugation of the plate and stored at -200C until further use. The supernatant was probed for IL-8 (DuoSet, cat no: DY208). Percentage reduction in secreted IL-8 and half-maximal inhibitory concentration of probiotic strains were derived using GraphPad Prism software (Version 8.0.1) as mentioned in below Table 8 and table 9. Table 8 S. No. Isolate IL-8 inhibition 10^7 CFU / mL 10^8 CFU / mL 1 ZMT110 + + 2 ZMT111 - + 3 ZMT112 + + 4 ZMT113 + + 5 ZMT114 - + 6 ZMT115 - + 7 ZMT116 + + 8 ZMT117 - + 9 ZMT118 - + 10 ZMT119 + + ZMT120 - - ZMT121 - - ZMT122 - - ZMT123 + + ZMT124 - - ZMT125 - + ZMT126 + + ZMT127 + + ZMT128 + + ZMT129 + + ZMT130 + + ZMT131 - + ZMT132 + + ZMT133 + + ZMT134 - - ZMT135 - + ZMT136 - + ZMT137 - + ZMT138 - - ZMT139 - + ZMT140 - - ZMT141 + + ZMT142 + ZMT143 - - ZMT144 - + ZMT145 - - ZMT146 - + ZMT147 + + ZMT148 + + ZMT149 - + 41 ZMT150 + + 42 ZMT151 - + 43 ZMT152 - + 44 ZMT153 - + 45 ZMT154 + + 46 ZMT155 + + 47 ZMT156 - + 48 ZMT157 + + 49 ZMT158 - + 50 ZMT159 - - 51 ZMT160 + + (+): reduced secreted IL-8 (-): Does not reduce secreted IL-8 Table 9 % IL-8 inhibition S. No. Isolate 10^6 CFU / mL 10^7 CFU / mL 10^8 CFU / mL 1ZMT11096 99 1012ZMT1110 0 1003ZMT11251 90 974ZMT11399 100 995ZMT1142 0 706ZMT1150 0 1007ZMT11650 59 898ZMT1170 46 609ZMT1180 49 5310 ZMT11952 39 6111 ZMT1200 0 012 ZMT1210 0 6613 ZMT12212 32 100ZMT123100 100 100ZMT12425 33 20ZMT1250 1 77ZMT12618 75 99ZMT12731 100 100ZMT12884 96 102ZMT12995 98 99ZMT13011 55 99ZMT1310 0 88ZMT13297 99 100ZMT133100 100 100ZMT1340 0 11ZMT1352 0 74ZMT13621 27 75ZMT1370 16 73ZMT13825 33 20ZMT1390 0 66ZMT1400 0 4ZMT14187 100 100ZMT1420 8 96ZMT14322 14 32ZMT1440 46 60ZMT14552 38 35ZMT1460 0 69ZMT14757 99 100ZMT1480 75 100ZMT14919 28 73ZMT1503 77 98ZMT15114 6 63ZMT1520 0 8444 ZMT15323 16 5945 ZMT1547 82 8246 ZMT1551 82 8247 ZMT1560 11 7248 ZMT15796 100 10049 ZMT1580 0 9150 ZMT1590 0 5Integrity-loss assessment assay: Caco2 (ATCC, cat no: HTB-37) cells were seeded in tissue culture treated 96 well plate (10,000 cells / well) in complete minimum essential medium with 10 % heat inactivated FBS and incubated in humidified CO2 incubator at 370C for 24 hrs. Next day cells were replenished with complete MEM (without antibiotics) and again incubated in CO2incubator at 370C for 24 hours. Next day, Caco2 cells were treated with increasing colony forming unit (CFU) ranging from 0 to 108, of the test bacterial culture. This was followed by addition of E. coli cells with (107CFU / mL final concentration). 4 hours post incubation, the supernatant was aspirated, and the cells were gently washed with PBS. The Caco2 cell layers were then stained with crystal violet for 1 min followed by wash with PBS, twice. The stain then solubilized in methanol and the absorbance was measured at 570 nm in a multimode reader. Percentage rescue of Caco2 monolayer and half-maximal protective concentration of probiotic strains were derived using GraphPad Prism software (Version 8.0.1) as mentioned in Table 10 and table 11. Table 10 Concentration of Isolate S. No. Isolate 10^7 CFU / mL 10^8 CFU / mL 1 ZMT110 + + 2 ZMT111 - 3 ZMT112 - + ZMT113 - + ZMT114 + + ZMT115 + + ZMT116 + + ZMT117 - + ZMT118 - ZMT119 + + ZMT120 + + ZMT121 - + ZMT122 - + ZMT123 + + ZMT124 - + ZMT125 - + ZMT126 + + ZMT127 + + ZMT128 + + ZMT129 - + ZMT130 + + ZMT131 + + ZMT132 + + ZMT133 + + ZMT134 + + ZMT135 + + ZMT136 + + ZMT137 + + ZMT138 + + ZMT139 + + ZMT140 + + ZMT141 + + ZMT142 - + 34 ZMT143 - - 35 ZMT144 + + 36 ZMT145 + + 37 ZMT146 + + 38 ZMT147 + + 39 ZMT148 + + 40 ZMT149 - + 41 ZMT150 - + 42 ZMT151 - + 43 ZMT152 + + 44 ZMT153 - + 45 ZMT154 - + 46 ZMT155 - + 47 ZMT156 - + 48 ZMT157 + + 49 ZMT158 + + 50 ZMT159 - - 51 ZMT160 - - (+): maintains Caco2 integrity (-): Does not maintain Caco2 integrity Table 11 % Caco2 monolayer rescue S. No. Isolate 10^6 CFU / mL 10^7 CFU / mL 10^8 CFU / mL 1ZMT1100 52 802ZMT11116 32 923ZMT1122 31 54ZMT11318 82 995ZMT11421 67 996ZMT11539 77 87ZMT11654 61 113ZMT1179 60 65ZMT1180 32 40ZMT1197 52 128ZMT12025 91 98ZMT12117 36 96ZMT12231 49 111ZMT12325 60 89ZMT12430 52 53ZMT1250 7 85ZMT1264 90 123ZMT12748 80 38ZMT128100 98 96ZMT1290 42 76ZMT13038 114 100ZMT13156 105 58ZMT13246 60 68ZMT13318 59 105ZMT13415 92 92ZMT1357 81 145ZMT1362 12 52ZMT13745 103 154ZMT13830 52 53ZMT13934 69 69ZMT14027 69 146ZMT14199 96 97ZMT14221 33 74ZMT1432 8 49ZMT1449 60 65ZMT1455 63 11537 ZMT14655 92 5538 ZMT147100 98 9339 ZMT1489 53 10340 ZMT1490 20 10541 ZMT1507 44 12442 ZMT15128 29 7343 ZMT15291 97 9644 ZMT1530 8 9845 ZMT15425 31 9046 ZMT1550 18 8547 ZMT1560 3 6848 ZMT15783 94 9249 ZMT15894 80 9850 ZMT1599 17 42Barrier Integrity assay: The gut epithelial barrier is a selective physical and biochemical shield that prevents the entry of pathogens, toxins, and antigens and maintains immune homeostasis by regulating interactions between the gut microbiota and the immune system. In Ulcerative Colitis (UC), this barrier becomes compromised, leading to increased intestinal permeability ("leaky gut"), disruption of tight junctions between epithelial cells followed by enhanced immune activation, as luminal antigens and bacteria penetrate the mucosa. This dysfunction is both a cause and consequence of inflammation in UC. Therapies targeting barrier repair would lead to the improvement in UC condition. In vitro barrier integrity studies are deeply relevant to understanding and modeling inflammatory bowel disease (IBD) as they typically use intestinal epithelial cell cultures or organoids to simulate the gut lining and assess how inflammation, cytokines, or drugs affect its permeability and function. These in vitro systems are valuable because they: Reflect human-specific responses better than some animal models. Help dissect the molecular pathways involved in epithelial barrier breakdown, a key feature in both Crohn’s disease and ulcerative colitis. In experiment of Barrier Integrity assay, Caco2 and HT29-MTX-E12 cells were mixed (9:1) and seeded a total of 30,000 cells in collagen coated transwell inserts (1 µ pore size) in a complete MEM medium containing 10 % heat inactivated FBS. The seeded inserts were maintained in a humidified CO2incubator for 21 days by changing the media every 2-3 days. On day 22, the cells were replenished with complete MEM without antibiotics and incubated in a CO2 incubator at 37 °C for 24 h. Next day, the cells in the apical chamber were treated with the combination of bacterial strains resuspended in complete MEM medium without antibiotics and a stimulant either cytokine mix (TNF-α, IL-1β, and IFN-γ; each 10 ng / mL) or pathogenic E. coli strain (107CFU). The basal chamber may or may not contain immune cells. This was followed by incubation in a CO2 incubator for 72 h. The apical and basal medium was carefully removed and replenished with sterile 1× Hank’s Balanced Salt Solution (HBSS), and allowed the inserts to equilibrate for 30 min in a CO2incubator at 37 °C. A fresh HBSS was then replenished. On the apical chamber, FITC- dextran (~4000 Da) was added at a final concentration of 200 µg / mL and incubated for 2 h in a CO2 incubator at 37 °C in a dark adaptive condition. Followed by incubation, a 100 µL of basal chamber content was transferred to 96- well round bottom black well plate and fluorescence was measured at excitation wavelength of 485 nm and emission wavelength of 520 nm. The percentage barrier protection was calculated with reference to vehicle control. The results are depicted in Figure 1 to Figure 4. It is inferred from the experiment that combination of the bacterial strains provides significant improvement in barrier integrity as compared to standard of care i.e. Visbiome. It is further inferred that combination of the bacterial strains provides significant improvement in barrier integrity as compared to individual bacterial strain and therefore demonstrates synergistic effect over individual bacterial strain. It is further inferred that the combination of bacterial strains provides significant improvement in barrier integrity for both, inflammation mediated as well as pathogen mediated damage of the intestinal barrier. Example 3: In-vivo Efficacy of combination of bacterial species in DSS- Induced Colitis Model Dextran Sulfate Salt (2.5 % DSS) in water, upon exposure to mice for 5 days, induces inflammation and gland loss with erosion in the colon Mice developed acute colitis with signs of diarrhea, gross rectal bleeding, and body weight loss after ingesting DSS. Gross changes are result of this DSS administration, which resemble the ulcerative colitis disease occurring in human, a subset of inflammatory bowel disease. The effect of isolated bacteria of the present invention, from the gut of NSG mice (imported from The Jackson Laboratory, ME, USA), is studied in the DSS induced ulcerative colitis model. Mice are assigned to different groups. Each group consisted of 8-10 animals. Different groups of animals receive oral formulation of various ZMT isolates while the control group of animals receives vehicle (Phosphate buffer saline) only. Animals are dosed with the ZMT isolates prior to the exposure to DSS and are continuing for the entire study period. The other group of animals are dosed with mesalamine i.e. standard of care. Mice body weights are measured daily. Scores of individual animals are recorded for each parameter, and sum of all scores (body weight loss, rectal bleeding & stool consistency) is reported as disease activity index (DAI). All data are expressed as mean + SEM and is considered significant if P<0.05 compared to control. Percentage inhibition (% Inhibition) on clinical score (DAI) is calculated using the following formula: % Inhibition = (Clinical score of vehicle control – Clinical score of Treated) / Clinical score of Vehicle control*100. The results of the experiment are demonstrated here in below Table 12 and 13; Table 12 Disease Treatment Colon Groups activity % % & length Index inhibition Improvement Dose (cm) (DAI) 7.53 ± Normal Control 0.0 ± 0.0 0.13 5.68 ± DSS control 5.2 ± 0.2 0.09 DSS+ZMT121 4.33 ± 5.78 ± (MTCC 25871) + 5B, BID 36.0 35.0 0.49 0.24 ZMT116 DSS+ZMT121 (MTCC 25871) + 5.78 ± 5B, BID 4.0 ± 0.5 41.0 34.0 ZMT122 (MTCC 0.17 25872) DSS+ZMT121 (MTCC 25871) + 5.69 ± 5B, BID 4.1 ± 0.5 38.0 30.0 ZMT128 (MTCC 0.10 25873) DSS+ZMT121 (MTCC 25871) + 3.88 ± 5.88 ± 5B, BID 42 39 ZMT129 (MTCC 0.48 0.12 25874) (50 mg / kg, 6.2 ± DSS + Mesalamine 3.8 ± 0.6 25.0 24.0 OD) 0.13 Table 13 Disease Colon activity % % Groups Dose length Index Inhibition Improvement (Cm) (DAI) 6.96 ± Normal Control 0.0 ± 0.0 0.14 5.17 ± DSS control 6.71 ± 0.68 0.11 DSS+ ZMT128 5.50 ± (MTCC 25873) alone 10B / day 4.75 ± 0.62 29 18 0.21 (5B, BID) DSS+ ZMT128 (MTCC 25873) (5B, 5.69 ± BID) + ZMT121 10B / day 4.14 ± 0.46 38 30 0.10 (MTCC 25871) (5B, BID) DSS+ ZMT116 alone 5.63 ± 10B / day 5.14 ± 0.40 23 26 (10B, BID) 0.12 DSS+ ZMT116 (5B, 5.78 ± BID) + ZMT121 (5B, 10B / day 4.33 ± 0.49 36 35 0.24 BID) DSS+ ZMT129 alone 5.41 ± 10B / day 5.43 ± 0.30 19 14 (10B, BID) 0.19 DSS+ ZMT129 (5B, 5.88 ± BID) + ZMT121 (5B, 10B / day 3.88 ± 0.48 42 39 0.12 BID) DSS+ ZMT122 (5B, 5.78 ± BID) + ZMT121 (5B, 10B / day 4.0 ± 0.50 41 34 0.17 BID) It is inferred from the experiment that combination of bacterial strains of the present invention provides significant improvement in colon length as compared to standard of care i.e. mesalamine. It is further inferred that combination of bacterial strains of the present invention provides significant improvement in disease activity index (DAI) as compared to standard of care i.e. mesalamine. It is further inferred that combination of bacterial strains of the present invention provides significant improvement in disease activity index (DAI) and significant improvement in colon length as compared to individual strain i.e. bacterial strain alone without combination of other strain(s). Incorporation by reference The entire disclosure of each of the patent documents and scientific articles referred to herein is incorporated by reference for all purposes. Equivalents The invention may be embodied in other specific forms without departing from the spirit or essential characteristics thereof. The foregoing embodiments are therefore to be considered in all respects illustrative rather than limiting the invention described herein. Scope of the invention is thus indicated by the appended claims rather than by the foregoing description, and all changes that come within the meaning and range of equivalency of the claims are intended to be embraced therein. REFERENCES 1. Spor et.al. (2011) Nat Rev Microbiol. 9(4):279-90. 2. Eckburg et al. (2005) Science. 10;308(5728): 1635-8. 3. Macpherson et al. (2001) Microbes Infect. 3(12): 1021-35 4. Macpherson et al. (2002) Cell Mol Life Sci. 59(12).2088-96. 5. Mazmanian et al. (2005) Cell 15; 122(1): 107-18. 6. Frank et al. (2007) PNAS 104(34): 13780-5. 7. Scanlan et al. (2006) J Clin Microbiol '. 44(l l):3980-8. 8. Kang et al. (2010) Inflamm Bowel Dis. 16(12):2034-42. 9. Machiels et al. (2013) Gut. 63(8)4275-83. 10. WO 2013 / 050792 11. WO 03 / 046580 12. WO 2013 / 008039 13. WO 2014 / 167338 14. Clinical Infectious Disease. 46 Suppl 2:S96-100 (2008). 15. BMJ. 347:f6471 (2013). 16. WO2015 / 095241 17. WO2015 / 156419 18. Lancet, 5(1): 17-302017 19. Intestinal Research 2017; 15(4):434-445. 20. Therapeutics and Clinical Risk Management 3, 893 (2007). 21. “Shaping the future of inflammatory bowel disease: a global research agenda for better management and public health response” Nature Reviews Gastroenterology & Hepatology | Volume 22 | June 2025 | 438–452 Please find below references to deposited biological material: Sr. ZMT MTCC Date of accession Culture Identity No Culture ID Number 1 ZMT148 MTCC 26-09-2024 Bacillus velezensis 25860 2 ZMT141 MTCC 26-09-2024 Enterobacter 25861 hormaechei 3 ZMT114 MTCC 03-12-2024 Streptococcus 25870 infantarius 4 ZMT122 MTCC 03-12-2024 Bacillus subtilis 25872 5 ZMT128 MTCC 03-12-2024 Bacillus subtilis 25873 6 ZMT129 MTCC 03-12-2024 Bacillus subtilis 25874 7 ZMT121 MTCC 03-12-2024 Streptococcus 25871 thermophilus ^ Depository Institute: CSIR-Institute of Microbial Technology (CSIR- IMTECH), Chandigarh ^ Address: Sector 39A Rd, 39A, Sector 39, Chandigarh, 160036 ^ MTCC Numbers Assigned: MTCC ZMT148 to MTCC ZMT121 (as listed above) ^ Source and Geographical Origin of Biological Material: NSG mice procured from The Jackson Laboratory, ME, USA

Claims

We claim, 1. A combination of bacterial species from genus Bacillus and genus Streptococcus.

2. The combination of bacterial species as claimed in claim 1 comprises species from genus Bacillus and species from genus Streptococcus, wherein species from genus Streptococcus is selected from Streptococcus acidominimus, Streptococcus agalactiae, Streptococcus anginosus, Streptococcus avium, Streptococcus bovis, Streptococcus canis, Streptococcus caprae, Streptococcus caprinus, Streptococcus castoreus, Streptococcus caviae, Streptococcus cecorum, Streptococcus cremoris, Streptococcus criceti, Streptococcus dentisani, Streptococcus difficile, Streptococcus durans, Streptococcus dysgalactiae, Streptococcus entericus, Streptococcus epidermidis, Streptococcus equi, Streptococcus faecalis, Streptococcus faecium, Streptococcus ferus, Streptococcus gallinarum, Streptococcus gallolyticus, Streptococcus halotolerans, Streptococcus hansenii, Streptococcus hillyeri, Streptococcus himalayensis, Streptococcus hominis, Streptococcus humanilactis, Streptococcus hyointestinalis, Streptococcus hyovaginalis, Streptococcus ilei, Streptococcus infantis, Streptococcus intermedius, Streptococcus intestinalis, Streptococcus lactis, Streptococcus merionis, Streptococcus microaerophilica, Streptococcus mitis, Streptococcus morbillorum, Streptococcus moroccensis, Streptococcus mutans, Streptococcus oligofermentans, Streptococcus oralis, Streptococcus ovis, Streptococcus pacificus, Streptococcus panodentis, Streptococcus parasanguinis, Streptococcus parasanguis, Streptococcus parasuis, Streptococcus parauberis, Streptococcus parvulus, Streptococcus pasteurianus, Streptococcus peroris, Streptococcus plantarum, Streptococcus pyogenes, Streptococcus respiraculi, Streptococcus saccharolyticus, Streptococcus salivarius, Streptococcus saliviloxodontae, Streptococcus sanguinis, Streptococcus sciuri, Streptococcus sinensis, Streptococcus sobrinus, Streptococcus suis,Streptococcus thalassemiae, Streptococcus thermophilus, Streptococcus thoraltensis, Streptococcus uberis, Streptococcus urinalis, Streptococcus ursoris, Streptococcus vaginalis, Streptococcus varani, Streptococcus vestibularis, Streptococcus vicugnae, Streptococcus vulneris, Streptococcus waius, Streptococcus xiaochunlingii, Streptococcus zalophi, PeptoStreptococcus anaerobius, PeptoStreptococcus asaccharolyticus, PeptoStreptococcus faecalis, PeptoStreptococcus harei, PeptoStreptococcus heliotrinreducens, PeptoStreptococcus magnus, PeptoStreptococcus octavius, PeptoStreptococcus parvulus, PeptoStreptococcus porci, PeptoStreptococcus prevotii, PeptoStreptococcus russellii, PeptoStreptococcus stomatis, PeptoStreptococcus tetradius, PeptoStreptococcus vaginalis, Streptococcus anginosus subsp. anginosus, Streptococcus constellatus subsp. pharyngis, Streptococcus dysgalactiae subsp. dysgalactiae, Streptococcus equi subsp. equi, Streptococcus faecium subsp. casseliflavus, Streptococcus gallolyticus subsp. gallolyticus, Streptococcus halichoeri subsp. halichoeri, Streptococcus infantarius subsp. coli, Streptococcus infantarius, Streptococcus lactis subsp. cremoris, Streptococcus lactis subsp. lactis, Streptococcus mutans subsp. sobrinus, Streptococcus oralis subsp. oralis, Streptococcus phocae subsp. salmonis, Streptococcus salivarius subsp. Salivarius or Streptococcus salivarius subsp. Thermophilus.

3. The combination as claimed in claim 1 comprises species from genus Streptococcus and species from genus Bacillus wherein species from genus Bacillus is selected from Bacillus acidocaldarius, Bacillus amyloliquefaciens, Bacillus amylolyticus, Bacillus anthracis, Bacillus aryabhattai , Bacillus cereus, Bacillus fusiformis, Bacillus globisporus, Bacillus hominis , Bacillus infantis, Bacillus insolitus, Bacillus larvae, Bacillus laterosporus, Bacillus lentimorbus, Bacillus lentus, Bacillus licheniformis, Bacillus macerans, Bacillus macquariensis, Bacillus megaterium, Bacillus mesophilus, Bacillus methylotrophicus, Bacillus multiformis, Bacillus mycoides, Bacillus oceani, Bacillus pantothenticus,Bacillus paralicheniformis, Bacillus paramycoides, Bacillus pasteurii, Bacillus perfringens, Bacillus polyfermenticus, Bacillus polymyxa, Bacillus popilliae, Bacillus pumilus, Bacillus pyogenes, Bacillus sanguinis, Bacillus siamensis, Bacillus spizizenii, Bacillus sporogenes, Bacillus stearothermophilus, Bacillus subtilis, Bacillus tequilensis, Bacillus thermoaerophilus, Bacillus thermodenitrificans, Bacillus thermolactis, Bacillus thermophilus, Bacillus thermotolerans, Bacillus thetaiotaomicron, Bacillus thuringiensis and Bacillus velezensis.

4. The combination as claimed in claim 1 comprising combination of bacterial species from genus Bacillus and genus Streptococcus wherein species of genus Bacillus are selected from claim 3 and species of genus Streptococcus are selected from claim 2.

5. The combination as claimed in claim 1 wherein combination comprising bacterial species from genus Bacillus is Bacillus subtilis having MTCC assigned number MTCC 25872 (ZMT122) or MTCC 25873 (ZMT128) or MTCC 25874 (ZMT129) and genus Streptococcus wherein species of genus Streptococcus are selected from claim 2.

6. The combination as claimed in claim 1 wherein combination comprising bacterial species from genus Bacillus is Bacillus velezensis having MTCC assigned number MTCC 25860 (ZMT148), and bacterial species of genus Streptococcus selected from claim 2.

7. The combination as claimed in claim 1 wherein combination comprising bacterial species from genus Streptococcus is Streptococcus thermophilus having MTCC number MTCC 25871 (ZMT121) and bacterial species of genus Bacillus selected from claim 3.

8. The combination as claimed in claim 1 wherein combination comprising bacterial species from genus Streptococcus is Streptococcus infantarius having MTCC assigned number MTCC 25870 (ZMT114), and bacterial species of genus Bacillus selected from claim 3.

9. The combination as claimed in claim 1 wherein combination comprising bacterial species from genus Bacillus is Bacillus subtilis or Bacillusvelezensis and bacterial species from genus Streptococcus is Streptococcus thermophilus or Streptococcus infantarius and suitable combinations thereof.

10. The combination as claimed in claim 1 wherein species from genus Bacillus is Bacillus subtilis has a MTCC number selected from MTCC 25872 (ZMT122), MTCC 25873 (ZMT128) and MTCC 25874 (ZMT129) and species from genus Streptococcus is selected from claim 2.

11. The combination as claimed in claim 1 wherein species from genus Streptococcus is Streptococcus thermophilus has a MTCC assigned number MTCC assigned number MTCC 25871 (ZMT121) and species from genus Bacillus is selected from claim 3.

12. The combination as claimed in any preceding claims comprising purified bacterial mixture of Bacillus subtilis and Streptococcus thermophilus wherein Bacillus subtilis has an MTCC assigned number MTCC 25874 (ZMT129) and Streptococcus thermophilus has an MTCC assigned number MTCC 25871 (ZMT121).

13. The combination as claimed in any preceding claims comprising purified bacterial mixture of Bacillus subtilis and Streptococcus thermophilus wherein Bacillus subtilis has an MTCC assigned number MTCC 25872 (ZMT122) and Streptococcus thermophilus has an MTCC assigned number MTCC 25871 (ZMT121).

14. The combination as claimed in any preceding claims comprising purified bacterial mixture of Bacillus subtilis and Streptococcus thermophilus wherein Bacillus subtilis has an MTCC assigned number MTCC 25873 (ZMT128) and Streptococcus thermophilus has an MTCC assigned number MTCC 25871 (ZMT121).

15. The combination as claimed in any preceding claims comprising purified bacterial mixture of Bacillus velezensis and Streptococcus thermophilus wherein Bacillus velezensis has an MTCC assigned number MTCC 25860 (ZMT148) and Streptococcus thermophilus has an MTCC assigned number MTCC 25871 (ZMT121).

16. The combination as claimed in any preceding claims comprising purified bacterial mixture of Bacillus velezensis and Streptococcus infantarius wherein Bacillus velezensis has an MTCC assigned number MTCC 25860 (ZMT148) and Streptococcus infantarius has an MTCC assigned number MTCC 25870 (ZMT114).

17. The combination as claimed in any preceding claims comprising purified bacterial mixture of Bacillus subtilis and Streptococcus infantarius wherein Bacillus subtilis has an MTCC assigned number MTCC 25872 (ZMT122) and Streptococcus infantarius has an MTCC assigned number MTCC 25870 (ZMT114).

18. The combination as claimed in any preceding claims comprising purified bacterial mixture of Bacillus subtilis and Streptococcus infantarius wherein Bacillus subtilis has an MTCC assigned number MTCC 25873 (ZMT128) and Streptococcus infantarius has an MTCC assigned number MTCC 25870 (ZMT114).

19. The combination as claimed in any preceding claims comprising purified bacterial mixture of Bacillus subtilis and Streptococcus infantarius wherein Bacillus subtilis has an MTCC assigned number MTCC 25874 (ZMT129) and Streptococcus infantarius has an MTCC assigned number MTCC 25870 (ZMT114).

20. The combination as claimed in any preceding claims comprising species from genus Bacillus and species from genus Streptococcus as claimed in claim 1 to 19, further comprises Enterobacter hormaechei having MTCC assigned number MTCC 25861 (ZMT141).

21. A pharmaceutical composition comprising purified bacterial mixture of the genus Bacillus and genus Streptococcus.

22. The pharmaceutical composition as claimed in claim 21 comprises species from genus Bacillus and species from genus Streptococcus, wherein species from genus Streptococcus is selected from Streptococcus acidominimus, Streptococcus agalactiae, Streptococcus anginosus, Streptococcus avium, Streptococcus bovis, Streptococcus canis, Streptococcus caprae,Streptococcus caprinus, Streptococcus castoreus, Streptococcus caviae, Streptococcus cecorum, Streptococcus cremoris, Streptococcus criceti, Streptococcus dentisani, Streptococcus difficile, Streptococcus durans, Streptococcus dysgalactiae, Streptococcus entericus, Streptococcus epidermidis, Streptococcus equi, Streptococcus faecalis, Streptococcus faecium, Streptococcus ferus, Streptococcus gallinarum, Streptococcus gallolyticus, Streptococcus halotolerans, Streptococcus hansenii, Streptococcus hillyeri, Streptococcus himalayensis, Streptococcus hominis, Streptococcus humanilactis, Streptococcus hyointestinalis, Streptococcus hyovaginalis, Streptococcus ilei, Streptococcus infantis, Streptococcus intermedius, Streptococcus intestinalis, Streptococcus lactis, Streptococcus merionis, Streptococcus microaerophilica, Streptococcus mitis, Streptococcus morbillorum, Streptococcus moroccensis, Streptococcus mutans, Streptococcus oligofermentans, Streptococcus oralis, Streptococcus ovis, Streptococcus pacificus, Streptococcus panodentis, Streptococcus parasanguinis, Streptococcus parasanguis, Streptococcus parasuis, Streptococcus parauberis, Streptococcus parvulus, Streptococcus pasteurianus, Streptococcus peroris, Streptococcus plantarum, Streptococcus pyogenes, Streptococcus respiraculi, Streptococcus saccharolyticus, Streptococcus salivarius, Streptococcus saliviloxodontae, Streptococcus sanguinis, Streptococcus sciuri, Streptococcus sinensis, Streptococcus sobrinus, Streptococcus suis, Streptococcus thalassemiae, Streptococcus thermophilus, Streptococcus thoraltensis, Streptococcus uberis, Streptococcus urinalis, Streptococcus ursoris, Streptococcus vaginalis, Streptococcus varani, Streptococcus vestibularis, Streptococcus vicugnae, Streptococcus vulneris, Streptococcus waius, Streptococcus xiaochunlingii, Streptococcus zalophi, PeptoStreptococcus anaerobius, PeptoStreptococcus asaccharolyticus, PeptoStreptococcus faecalis, PeptoStreptococcus harei, PeptoStreptococcus heliotrinreducens, PeptoStreptococcus magnus, PeptoStreptococcus octavius, PeptoStreptococcus parvulus, PeptoStreptococcus porci,PeptoStreptococcus prevotii, PeptoStreptococcus russellii, PeptoStreptococcus stomatis, PeptoStreptococcus tetradius, PeptoStreptococcus vaginalis, Streptococcus anginosus subsp. anginosus, Streptococcus constellatus subsp. pharyngis, Streptococcus dysgalactiae subsp. dysgalactiae, Streptococcus equi subsp. equi, Streptococcus faecium subsp. casseliflavus, Streptococcus gallolyticus subsp. gallolyticus, Streptococcus halichoeri subsp. halichoeri, Streptococcus infantarius subsp. coli, Streptococcus infantarius, Streptococcus lactis subsp. cremoris, Streptococcus lactis subsp. lactis, Streptococcus mutans subsp. sobrinus, Streptococcus oralis subsp. oralis, Streptococcus phocae subsp. salmonis, Streptococcus salivarius subsp. Salivarius or Streptococcus salivarius subsp. Thermophilus.

23. The pharmaceutical composition as claimed in claim 21 comprises species from genus Streptococcus and species from genus Bacillus wherein species from genus Bacillus is selected from Bacillus acidocaldarius, Bacillus amyloliquefaciens, Bacillus amylolyticus, Bacillus anthracis, Bacillus aryabhattai , Bacillus cereus, Bacillus fusiformis, Bacillus globisporus, Bacillus hominis , Bacillus infantis, Bacillus insolitus, Bacillus larvae, Bacillus laterosporus, Bacillus lentimorbus, Bacillus lentus, Bacillus licheniformis, Bacillus macerans, Bacillus macquariensis, Bacillus megaterium, Bacillus mesophilus, Bacillus methylotrophicus, Bacillus multiformis, Bacillus mycoides, Bacillus oceani, Bacillus pantothenticus, Bacillus paralicheniformis, Bacillus paramycoides, Bacillus pasteurii, Bacillus perfringens, Bacillus polyfermenticus, Bacillus polymyxa, Bacillus popilliae, Bacillus pumilus, Bacillus pyogenes, Bacillus sanguinis, Bacillus siamensis, Bacillus spizizenii, Bacillus sporogenes, Bacillus stearothermophilus, Bacillus subtilis, Bacillus tequilensis, Bacillus thermoaerophilus, Bacillus thermodenitrificans, Bacillus thermolactis, Bacillus thermophilus, Bacillus thermotolerans, Bacillus thetaiotaomicron, Bacillus thuringiensis and Bacillus velezensis.

24. The pharmaceutical composition as claimed in claim 21 comprising combination of bacterial species from genus Bacillus and genus Streptococcus wherein species of genus Bacillus are selected from claim 23 and species of genus Streptococcus are selected from claim 22.

25. The pharmaceutical composition as claimed in claim 21 wherein composition comprising bacterial species from genus Bacillus is Bacillus subtilis having MTCC assigned number MTCC 25872 (ZMT122) or MTCC 25873 (ZMT128) or MTCC 25874 (ZMT129) and genus Streptococcus wherein species of genus Streptococcus are selected from claim 22.

26. The pharmaceutical composition as claimed in claim 21 wherein composition comprising bacterial species from genus Bacillus is Bacillus velezensis having MTCC assigned number MTCC 25860 (ZMT148), and bacterial species of genus Streptococcus selected from claim 22.

27. The pharmaceutical composition as claimed in claim 21 wherein composition comprising bacterial species from genus Streptococcus is Streptococcus thermophilus having MTCC number MTCC 25871 (ZMT121) and bacterial species of genus Bacillus selected from claim 23.

28. The pharmaceutical composition as claimed in claim 21 wherein composition comprising bacterial species from genus Streptococcus is Streptococcus infantarius having MTCC assigned number MTCC 25870 (ZMT114), and bacterial species of genus Bacillus selected from claim 23.

29. The pharmaceutical composition as claimed in claim 21 wherein composition comprising bacterial species from genus Bacillus is Bacillus subtilis or Bacillus velezensis and bacterial species from genus Streptococcus is Streptococcus thermophilus or Streptococcus infantarius and suitable combinations thereof.

30. The pharmaceutical composition as claimed in claim 21 wherein composition comprising bacterial species from genus Bacillus is Bacillus subtilis has a MTCC number selected from MTCC 25872 (ZMT122), MTCC 25873 (ZMT128) and MTCC 25874 (ZMT129) and species from genus Streptococcus is selected from claim 22.

31. The pharmaceutical composition as claimed in claim 21 wherein composition comprising bacterial species from genus Streptococcus is Streptococcus thermophilus has a MTCC assigned number MTCC 25871 (ZMT121) and species from genus Bacillus is selected from claim 23.

32. The pharmaceutical composition as claimed in claim 21 comprising purified bacterial mixture of Bacillus subtilis and Streptococcus thermophilus wherein Bacillus subtilis has an MTCC assigned number MTCC 25874 (ZMT129) and Streptococcus thermophilus has an MTCC assigned number MTCC 25871 (ZMT121).

33. The pharmaceutical composition as claimed in claim 21 comprising purified bacterial mixture of Bacillus subtilis and Streptococcus thermophilus wherein Bacillus subtilis has an MTCC assigned number MTCC 25872 (ZMT122) and Streptococcus thermophilus has an MTCC assigned number MTCC 25871 (ZMT121).

34. The pharmaceutical composition as claimed in claim 21 comprising purified bacterial mixture of Bacillus subtilis and Streptococcus thermophilus wherein Bacillus subtilis has an MTCC assigned number MTCC 25873 (ZMT128) and Streptococcus thermophilus has an MTCC assigned number MTCC 25871 (ZMT121).

35. The pharmaceutical composition as claimed in claim 21 comprising purified bacterial mixture of Bacillus velezensis and Streptococcus thermophilus wherein Bacillus velezensis has an MTCC assigned number MTCC 25860 (ZMT148) and Streptococcus thermophilus has an MTCC assigned number MTCC 25871 (ZMT121).

36. The pharmaceutical composition as claimed in claim 21 comprising purified bacterial mixture of Bacillus velezensis and Streptococcus infantarius wherein Bacillus velezensis has an MTCC assigned number MTCC 25860 (ZMT148) and Streptococcus infantarius has an MTCC assigned number MTCC 25870 (ZMT114).

37. The pharmaceutical composition as claimed in claim 21 comprising purified bacterial mixture of Bacillus subtilis and Streptococcus infantarius whereinBacillus subtilis has an MTCC assigned number MTCC 25872 (ZMT122) and Streptococcus infantarius has an MTCC assigned number MTCC 25870 (ZMT114).

38. The pharmaceutical composition as claimed in claim 21 comprising purified bacterial mixture of Bacillus subtilis and Streptococcus infantarius wherein Bacillus subtilis has an MTCC assigned number MTCC 25873 (ZMT128) and Streptococcus infantarius has an MTCC assigned number MTCC 25870 (ZMT114).

39. The pharmaceutical composition as claimed in claim 21 comprising purified bacterial mixture of Bacillus subtilis and Streptococcus infantarius wherein Bacillus subtilis has an MTCC assigned number MTCC 25874 (ZMT129) and Streptococcus infantarius has an MTCC assigned number MTCC 25870 (ZMT114).

40. The pharmaceutical composition comprising combination as claimed in claim 1 to 20, wherein a dose of the pharmaceutical composition comprises between 103to 1013colony forming units (CFUs), preferably between 105to 1012colony forming units (CFUs).

41. The pharmaceutical composition comprising combination of species from genus Bacillus and species from genus Streptococcus as claimed in claim 1 to 19, further comprises Enterobacter hormaechei having MTCC assigned number MTCC 25861 (ZMT141).

42. A method for treating and / or preventing inflammatory bowel disease (IBD), ulcerative colitis (UC) and / or pouchitis in a subject, wherein the method comprising administering to the subject a therapeutically effective amount of combination of species from genus Bacillus and species from genus Streptococcus as claimed in claim 1 to 19.

43. A method for treating and / or preventing inflammatory bowel disease (IBD), ulcerative colitis (UC) and / or pouchitis in a subject, wherein the method comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition as claimed any of claim 21 to claim 39.

44. Use of the combination as claimed in claim 1 to 19 in treating and / or preventing inflammatory bowel disease (IBD), ulcerative colitis (UC) and / or pouchitis in a subject.

45. Use of the pharmaceutical composition as claimed in claim 21 to 39 in treating and / or preventing inflammatory bowel disease (IBD), ulcerative colitis (UC) and / or pouchitis in a subject.

46. The pharmaceutical composition as claimed in claim 21 to 39 wherein bacterial mixture are lyophilized or spray-dried or in spore form or in vegetative form or in heat killed form or in attenuated form.

47. The pharmaceutical composition as claimed in claim 21 to 39 is co- administered with other therapeutic agents such as immunotherapeutics, anti-angiogenic agents, cytokines, hormones, antibodies, polynucleotides, photodynamic therapeutic agents, non-steroid anti-inflammatory medications, antihistamines, alpha-adrenergic agonists, steroids, and any combination thereof.

48. The pharmaceutical composition as claimed in claim 21 to 39 further comprises suitable excipients or suitable pharmaceutical carriers.

Images